#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Decreased Functional Connectivity of Insular Cortex in Drug Naïve First Episode Schizophrenia: In Relation to Symptom Severity
#Text=Background
#Text=This study was to examine the insular cortical functional connectivity in drug naïve patients with first episode schizophrenia and to explore the relationship between the connectivity and the severity of clinical symptoms.
1-1	0-9	Decreased	_	
1-2	10-20	Functional	_	
1-3	21-33	Connectivity	_	
1-4	34-36	of	_	
1-5	37-44	Insular	_	
1-6	45-51	Cortex	_	
1-7	52-54	in	_	
1-8	55-59	Drug	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[1]	
1-9	60-65	Naïve	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[1]	
1-10	66-71	First	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[2]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-11	72-79	Episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[2]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-12	80-93	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[2]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
1-13	93-94	:	_	
1-14	95-97	In	_	
1-15	98-106	Relation	_	
1-16	107-109	to	_	
1-17	110-117	Symptom	_	
1-18	118-126	Severity	_	
1-19	127-137	Background	_	
1-20	138-142	This	_	
1-21	143-148	study	_	
1-22	149-152	was	_	
1-23	153-155	to	_	
1-24	156-163	examine	_	
1-25	164-167	the	_	
1-26	168-175	insular	_	
1-27	176-184	cortical	_	
1-28	185-195	functional	_	
1-29	196-208	connectivity	_	
1-30	209-211	in	_	
1-31	212-216	drug	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[5]	
1-32	217-222	naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[5]	
1-33	223-231	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[5]	
1-34	232-236	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
1-35	237-242	first	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]	
1-36	243-250	episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]	
1-37	251-264	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[6]	
1-38	265-268	and	_	
1-39	269-271	to	_	
1-40	272-279	explore	_	
1-41	280-283	the	_	
1-42	284-296	relationship	_	
1-43	297-304	between	_	
1-44	305-308	the	_	
1-45	309-321	connectivity	_	
1-46	322-325	and	_	
1-47	326-329	the	_	
1-48	330-338	severity	_	
1-49	339-341	of	_	
1-50	342-350	clinical	_	
1-51	351-359	symptoms	_	
1-52	359-360	.	_	

#Text=Methods
#Text=Thirty-seven drug naïve patients with schizophrenia and 25 healthy controls were enrolled in this study.
2-1	361-368	Methods	_	
2-2	369-381	Thirty-seven	_	
2-3	382-386	drug	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[8]	
2-4	387-392	naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[8]	
2-5	393-401	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[8]	
2-6	402-406	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[8]	
2-7	407-420	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[8]	
2-8	421-424	and	_	
2-9	425-427	25	_	
2-10	428-435	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
2-11	436-444	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
2-12	445-449	were	_	
2-13	450-458	enrolled	_	
2-14	459-461	in	_	
2-15	462-466	this	_	
2-16	467-472	study	_	
2-17	472-473	.	_	

#Text=A seed-based approach was used to analyze the resting-state functional imaging data.
3-1	474-475	A	_	
3-2	476-486	seed-based	_	
3-3	487-495	approach	_	
3-4	496-499	was	_	
3-5	500-504	used	_	
3-6	505-507	to	_	
3-7	508-515	analyze	_	
3-8	516-519	the	_	
3-9	520-533	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
3-10	534-544	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
3-11	545-552	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
3-12	553-557	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	
3-13	557-558	.	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[10]	

#Text=Insular cortical connectivity maps were bilaterally extracted for group comparison and validated by voxel-based morphometry (VBM) analysis.
4-1	559-566	Insular	_	
4-2	567-575	cortical	_	
4-3	576-588	connectivity	_	
4-4	589-593	maps	_	
4-5	594-598	were	_	
4-6	599-610	bilaterally	_	
4-7	611-620	extracted	_	
4-8	621-624	for	_	
4-9	625-630	group	_	
4-10	631-641	comparison	_	
4-11	642-645	and	_	
4-12	646-655	validated	_	
4-13	656-658	by	_	
4-14	659-670	voxel-based	_	
4-15	671-682	morphometry	_	
4-16	683-684	(	_	
4-17	684-687	VBM	_	
4-18	687-688	)	_	
4-19	689-697	analysis	_	
4-20	697-698	.	_	

#Text=Clinical symptoms were measured using the Positive and Negative Syndrome Scale (PANSS).
5-1	699-707	Clinical	_	
5-2	708-716	symptoms	_	
5-3	717-721	were	_	
5-4	722-730	measured	_	
5-5	731-736	using	_	
5-6	737-740	the	_	
5-7	741-749	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-8	750-753	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-9	754-762	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-10	763-771	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-11	772-777	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-12	778-779	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-13	779-784	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-14	784-785	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[11]	
5-15	785-786	.	_	

#Text=Results
#Text=There were significant reductions in the right insular cortical connectivity with the Heschl’s gyrus, anterior cingulate cortex (ACC), and caudate (p’s<0.001) in the patient group compared with the healthy control (HC) group.
6-1	787-794	Results	_	
6-2	795-800	There	_	
6-3	801-805	were	_	
6-4	806-817	significant	_	
6-5	818-828	reductions	_	
6-6	829-831	in	_	
6-7	832-835	the	_	
6-8	836-841	right	_	
6-9	842-849	insular	_	
6-10	850-858	cortical	_	
6-11	859-871	connectivity	_	
6-12	872-876	with	_	
6-13	877-880	the	_	
6-14	881-887	Heschl	_	
6-15	887-888	’	_	
6-16	888-889	s	_	
6-17	890-895	gyrus	_	
6-18	895-896	,	_	
6-19	897-905	anterior	_	
6-20	906-915	cingulate	_	
6-21	916-922	cortex	_	
6-22	923-924	(	_	
6-23	924-927	ACC	_	
6-24	927-928	)	_	
6-25	928-929	,	_	
6-26	930-933	and	_	
6-27	934-941	caudate	_	
6-28	942-943	(	_	
6-29	943-944	p	_	
6-30	944-945	’	_	
6-31	945-946	s	_	
6-32	946-947	<	_	
6-33	947-952	0.001	_	
6-34	952-953	)	_	
6-35	954-956	in	_	
6-36	957-960	the	_	
6-37	961-968	patient	_	
6-38	969-974	group	_	
6-39	975-983	compared	_	
6-40	984-988	with	_	
6-41	989-992	the	_	
6-42	993-1000	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-43	1001-1008	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-44	1009-1010	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-45	1010-1012	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-46	1012-1013	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
6-47	1014-1019	group	_	
6-48	1019-1020	.	_	

#Text=Reduced right insular cortical connectivity with the Heschl’s gyrus was further confirmed in the VBM analysis (FDR corrected p<0.05).
7-1	1021-1028	Reduced	_	
7-2	1029-1034	right	_	
7-3	1035-1042	insular	_	
7-4	1043-1051	cortical	_	
7-5	1052-1064	connectivity	_	
7-6	1065-1069	with	_	
7-7	1070-1073	the	_	
7-8	1074-1080	Heschl	_	
7-9	1080-1081	’	_	
7-10	1081-1082	s	_	
7-11	1083-1088	gyrus	_	
7-12	1089-1092	was	_	
7-13	1093-1100	further	_	
7-14	1101-1110	confirmed	_	
7-15	1111-1113	in	_	
7-16	1114-1117	the	_	
7-17	1118-1121	VBM	_	
7-18	1122-1130	analysis	_	
7-19	1131-1132	(	_	
7-20	1132-1135	FDR	_	
7-21	1136-1145	corrected	_	
7-22	1146-1147	p	_	
7-23	1147-1148	<	_	
7-24	1148-1152	0.05	_	
7-25	1152-1153	)	_	
7-26	1153-1154	.	_	

#Text=Within the patient group, there was a significant positive relationship between the right insula-Heschl’s connectivity and PANSS general psychopathology scores (r = 0.384, p = 0.019).
8-1	1155-1161	Within	_	
8-2	1162-1165	the	_	
8-3	1166-1173	patient	_	
8-4	1174-1179	group	_	
8-5	1179-1180	,	_	
8-6	1181-1186	there	_	
8-7	1187-1190	was	_	
8-8	1191-1192	a	_	
8-9	1193-1204	significant	_	
8-10	1205-1213	positive	_	
8-11	1214-1226	relationship	_	
8-12	1227-1234	between	_	
8-13	1235-1238	the	_	
8-14	1239-1244	right	_	
8-15	1245-1258	insula-Heschl	_	
8-16	1258-1259	’	_	
8-17	1259-1260	s	_	
8-18	1261-1273	connectivity	_	
8-19	1274-1277	and	_	
8-20	1278-1283	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
8-21	1284-1291	general	_	
8-22	1292-1307	psychopathology	_	
8-23	1308-1314	scores	_	
8-24	1315-1316	(	_	
8-25	1316-1317	r	_	
8-26	1318-1319	=	_	
8-27	1320-1325	0.384	_	
8-28	1325-1326	,	_	
8-29	1327-1328	p	_	
8-30	1329-1330	=	_	
8-31	1331-1336	0.019	_	
8-32	1336-1337	)	_	
8-33	1337-1338	.	_	

#Text=Conclusion
#Text=Reduced insula-Heschl’s functional connectivity is present in drug naïve patients with first episode schizophrenia, which might be related to the manifestation of clinical symptoms.
#Text=1.
9-1	1339-1349	Conclusion	_	
9-2	1350-1357	Reduced	_	
9-3	1358-1371	insula-Heschl	_	
9-4	1371-1372	’	_	
9-5	1372-1373	s	_	
9-6	1374-1384	functional	_	
9-7	1385-1397	connectivity	_	
9-8	1398-1400	is	_	
9-9	1401-1408	present	_	
9-10	1409-1411	in	_	
9-11	1412-1416	drug	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[14]	
9-12	1417-1422	naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[14]	
9-13	1423-1431	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[14]	
9-14	1432-1436	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]	
9-15	1437-1442	first	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[15]	
9-16	1443-1450	episode	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[15]	
9-17	1451-1464	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[13]|http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis[15]	
9-18	1464-1465	,	_	
9-19	1466-1471	which	_	
9-20	1472-1477	might	_	
9-21	1478-1480	be	_	
9-22	1481-1488	related	_	
9-23	1489-1491	to	_	
9-24	1492-1495	the	_	
9-25	1496-1509	manifestation	_	
9-26	1510-1512	of	_	
9-27	1513-1521	clinical	_	
9-28	1522-1530	symptoms	_	
9-29	1530-1531	.	_	
9-30	1532-1533	1	_	
9-31	1533-1534	.	_	

#Text=Introduction
#Text=Schizophrenia, a severe psychiatric disorder characterized by positive and negative symptoms and cognitive deficits, has long been hypothesized as a disorder of brain connectivity.
10-1	1535-1547	Introduction	_	
10-2	1548-1561	Schizophrenia	_	
10-3	1561-1562	,	_	
10-4	1563-1564	a	_	
10-5	1565-1571	severe	_	
10-6	1572-1583	psychiatric	_	
10-7	1584-1592	disorder	_	
10-8	1593-1606	characterized	_	
10-9	1607-1609	by	_	
10-10	1610-1618	positive	_	
10-11	1619-1622	and	_	
10-12	1623-1631	negative	_	
10-13	1632-1640	symptoms	_	
10-14	1641-1644	and	_	
10-15	1645-1654	cognitive	_	
10-16	1655-1663	deficits	_	
10-17	1663-1664	,	_	
10-18	1665-1668	has	_	
10-19	1669-1673	long	_	
10-20	1674-1678	been	_	
10-21	1679-1691	hypothesized	_	
10-22	1692-1694	as	_	
10-23	1695-1696	a	_	
10-24	1697-1705	disorder	_	
10-25	1706-1708	of	_	
10-26	1709-1714	brain	_	
10-27	1715-1727	connectivity	_	
10-28	1727-1728	.	_	

#Text=Disrupted brain development can lead to abnormal neural connectivity or network, which may cause abnormal information processing and integration, and clinical symptoms including psychosis.
11-1	1729-1738	Disrupted	_	
11-2	1739-1744	brain	_	
11-3	1745-1756	development	_	
11-4	1757-1760	can	_	
11-5	1761-1765	lead	_	
11-6	1766-1768	to	_	
11-7	1769-1777	abnormal	_	
11-8	1778-1784	neural	_	
11-9	1785-1797	connectivity	_	
11-10	1798-1800	or	_	
11-11	1801-1808	network	_	
11-12	1808-1809	,	_	
11-13	1810-1815	which	_	
11-14	1816-1819	may	_	
11-15	1820-1825	cause	_	
11-16	1826-1834	abnormal	_	
11-17	1835-1846	information	_	
11-18	1847-1857	processing	_	
11-19	1858-1861	and	_	
11-20	1862-1873	integration	_	
11-21	1873-1874	,	_	
11-22	1875-1878	and	_	
11-23	1879-1887	clinical	_	
11-24	1888-1896	symptoms	_	
11-25	1897-1906	including	_	
11-26	1907-1916	psychosis	_	
11-27	1916-1917	.	_	

#Text=It has been well established that the insula cortex is an anatomical gateway between the visual, olfactory, auditory, somatosensory cortices and the limbic structures.
12-1	1918-1920	It	_	
12-2	1921-1924	has	_	
12-3	1925-1929	been	_	
12-4	1930-1934	well	_	
12-5	1935-1946	established	_	
12-6	1947-1951	that	_	
12-7	1952-1955	the	_	
12-8	1956-1962	insula	_	
12-9	1963-1969	cortex	_	
12-10	1970-1972	is	_	
12-11	1973-1975	an	_	
12-12	1976-1986	anatomical	_	
12-13	1987-1994	gateway	_	
12-14	1995-2002	between	_	
12-15	2003-2006	the	_	
12-16	2007-2013	visual	_	
12-17	2013-2014	,	_	
12-18	2015-2024	olfactory	_	
12-19	2024-2025	,	_	
12-20	2026-2034	auditory	_	
12-21	2034-2035	,	_	
12-22	2036-2049	somatosensory	_	
12-23	2050-2058	cortices	_	
12-24	2059-2062	and	_	
12-25	2063-2066	the	_	
12-26	2067-2073	limbic	_	
12-27	2074-2084	structures	_	
12-28	2084-2085	.	_	

#Text=Secluded deep within the lateral sulcus of the human brain, the insular cortex is part of an extended network of neuronal pathways connecting to the anterior cingulate cortex, temporal lobe, parietal lobe, hippocampus, amygdala, olfactory cortex, and thalamus.
13-1	2086-2094	Secluded	_	
13-2	2095-2099	deep	_	
13-3	2100-2106	within	_	
13-4	2107-2110	the	_	
13-5	2111-2118	lateral	_	
13-6	2119-2125	sulcus	_	
13-7	2126-2128	of	_	
13-8	2129-2132	the	_	
13-9	2133-2138	human	_	
13-10	2139-2144	brain	_	
13-11	2144-2145	,	_	
13-12	2146-2149	the	_	
13-13	2150-2157	insular	_	
13-14	2158-2164	cortex	_	
13-15	2165-2167	is	_	
13-16	2168-2172	part	_	
13-17	2173-2175	of	_	
13-18	2176-2178	an	_	
13-19	2179-2187	extended	_	
13-20	2188-2195	network	_	
13-21	2196-2198	of	_	
13-22	2199-2207	neuronal	_	
13-23	2208-2216	pathways	_	
13-24	2217-2227	connecting	_	
13-25	2228-2230	to	_	
13-26	2231-2234	the	_	
13-27	2235-2243	anterior	_	
13-28	2244-2253	cingulate	_	
13-29	2254-2260	cortex	_	
13-30	2260-2261	,	_	
13-31	2262-2270	temporal	_	
13-32	2271-2275	lobe	_	
13-33	2275-2276	,	_	
13-34	2277-2285	parietal	_	
13-35	2286-2290	lobe	_	
13-36	2290-2291	,	_	
13-37	2292-2303	hippocampus	_	
13-38	2303-2304	,	_	
13-39	2305-2313	amygdala	_	
13-40	2313-2314	,	_	
13-41	2315-2324	olfactory	_	
13-42	2325-2331	cortex	_	
13-43	2331-2332	,	_	
13-44	2333-2336	and	_	
13-45	2337-2345	thalamus	_	
13-46	2345-2346	.	_	

#Text=The ventromedial prefrontal cortex, posterior cingulate cortex, bilateral inferior parietal cortex and middle temporal lobe are parts of default mode network (DMN).
14-1	2347-2350	The	_	
14-2	2351-2363	ventromedial	_	
14-3	2364-2374	prefrontal	_	
14-4	2375-2381	cortex	_	
14-5	2381-2382	,	_	
14-6	2383-2392	posterior	_	
14-7	2393-2402	cingulate	_	
14-8	2403-2409	cortex	_	
14-9	2409-2410	,	_	
14-10	2411-2420	bilateral	_	
14-11	2421-2429	inferior	_	
14-12	2430-2438	parietal	_	
14-13	2439-2445	cortex	_	
14-14	2446-2449	and	_	
14-15	2450-2456	middle	_	
14-16	2457-2465	temporal	_	
14-17	2466-2470	lobe	_	
14-18	2471-2474	are	_	
14-19	2475-2480	parts	_	
14-20	2481-2483	of	_	
14-21	2484-2491	default	_	
14-22	2492-2496	mode	_	
14-23	2497-2504	network	_	
14-24	2505-2506	(	_	
14-25	2506-2509	DMN	_	
14-26	2509-2510	)	_	
14-27	2510-2511	.	_	

#Text=The central executive network (CEN) consists of mainly the dorsolateral prefrontal cortex and posterior parietal cortex.
15-1	2512-2515	The	_	
15-2	2516-2523	central	_	
15-3	2524-2533	executive	_	
15-4	2534-2541	network	_	
15-5	2542-2543	(	_	
15-6	2543-2546	CEN	_	
15-7	2546-2547	)	_	
15-8	2548-2556	consists	_	
15-9	2557-2559	of	_	
15-10	2560-2566	mainly	_	
15-11	2567-2570	the	_	
15-12	2571-2583	dorsolateral	_	
15-13	2584-2594	prefrontal	_	
15-14	2595-2601	cortex	_	
15-15	2602-2605	and	_	
15-16	2606-2615	posterior	_	
15-17	2616-2624	parietal	_	
15-18	2625-2631	cortex	_	
15-19	2631-2632	.	_	

#Text=The salience network (SN) includes primarily the anterior insular cortex and dorsal anterior cingulate cortex.
16-1	2633-2636	The	_	
16-2	2637-2645	salience	_	
16-3	2646-2653	network	_	
16-4	2654-2655	(	_	
16-5	2655-2657	SN	_	
16-6	2657-2658	)	_	
16-7	2659-2667	includes	_	
16-8	2668-2677	primarily	_	
16-9	2678-2681	the	_	
16-10	2682-2690	anterior	_	
16-11	2691-2698	insular	_	
16-12	2699-2705	cortex	_	
16-13	2706-2709	and	_	
16-14	2710-2716	dorsal	_	
16-15	2717-2725	anterior	_	
16-16	2726-2735	cingulate	_	
16-17	2736-2742	cortex	_	
16-18	2742-2743	.	_	

#Text=Apparentlythe insular cortex functions as a multimodal sensory integration region.
17-1	2744-2757	Apparentlythe	_	
17-2	2758-2765	insular	_	
17-3	2766-2772	cortex	_	
17-4	2773-2782	functions	_	
17-5	2783-2785	as	_	
17-6	2786-2787	a	_	
17-7	2788-2798	multimodal	_	
17-8	2799-2806	sensory	_	
17-9	2807-2818	integration	_	
17-10	2819-2825	region	_	
17-11	2825-2826	.	_	

#Text=In addition, the insular cortex plays an important role in emotion processing including interoceptive awareness, anticipation, evaluation of emotional stimuli, self-awareness, episodic memory, executive function, attention, and saliency processing.
18-1	2827-2829	In	_	
18-2	2830-2838	addition	_	
18-3	2838-2839	,	_	
18-4	2840-2843	the	_	
18-5	2844-2851	insular	_	
18-6	2852-2858	cortex	_	
18-7	2859-2864	plays	_	
18-8	2865-2867	an	_	
18-9	2868-2877	important	_	
18-10	2878-2882	role	_	
18-11	2883-2885	in	_	
18-12	2886-2893	emotion	_	
18-13	2894-2904	processing	_	
18-14	2905-2914	including	_	
18-15	2915-2928	interoceptive	_	
18-16	2929-2938	awareness	_	
18-17	2938-2939	,	_	
18-18	2940-2952	anticipation	_	
18-19	2952-2953	,	_	
18-20	2954-2964	evaluation	_	
18-21	2965-2967	of	_	
18-22	2968-2977	emotional	_	
18-23	2978-2985	stimuli	_	
18-24	2985-2986	,	_	
18-25	2987-3001	self-awareness	_	
18-26	3001-3002	,	_	
18-27	3003-3011	episodic	_	
18-28	3012-3018	memory	_	
18-29	3018-3019	,	_	
18-30	3020-3029	executive	_	
18-31	3030-3038	function	_	
18-32	3038-3039	,	_	
18-33	3040-3049	attention	_	
18-34	3049-3050	,	_	
18-35	3051-3054	and	_	
18-36	3055-3063	saliency	_	
18-37	3064-3074	processing	_	
18-38	3074-3075	.	_	

#Text=Recently, the insula cortex has attracted significant attention in schizophrenia research.
19-1	3076-3084	Recently	_	
19-2	3084-3085	,	_	
19-3	3086-3089	the	_	
19-4	3090-3096	insula	_	
19-5	3097-3103	cortex	_	
19-6	3104-3107	has	_	
19-7	3108-3117	attracted	_	
19-8	3118-3129	significant	_	
19-9	3130-3139	attention	_	
19-10	3140-3142	in	_	
19-11	3143-3156	schizophrenia	_	
19-12	3157-3165	research	_	
19-13	3165-3166	.	_	

#Text=The aberrant functional and structural alterations in insular cortex have been frequently reported in schizophrenia including reduced gray matter volume, thickness, and surface area, decreased white matter integrity (measured by fractional anisotropy or mean diffusivity), and altered functional activity under various tasks or during resting state.
20-1	3167-3170	The	_	
20-2	3171-3179	aberrant	_	
20-3	3180-3190	functional	_	
20-4	3191-3194	and	_	
20-5	3195-3205	structural	_	
20-6	3206-3217	alterations	_	
20-7	3218-3220	in	_	
20-8	3221-3228	insular	_	
20-9	3229-3235	cortex	_	
20-10	3236-3240	have	_	
20-11	3241-3245	been	_	
20-12	3246-3256	frequently	_	
20-13	3257-3265	reported	_	
20-14	3266-3268	in	_	
20-15	3269-3282	schizophrenia	_	
20-16	3283-3292	including	_	
20-17	3293-3300	reduced	_	
20-18	3301-3305	gray	_	
20-19	3306-3312	matter	_	
20-20	3313-3319	volume	_	
20-21	3319-3320	,	_	
20-22	3321-3330	thickness	_	
20-23	3330-3331	,	_	
20-24	3332-3335	and	_	
20-25	3336-3343	surface	_	
20-26	3344-3348	area	_	
20-27	3348-3349	,	_	
20-28	3350-3359	decreased	_	
20-29	3360-3365	white	_	
20-30	3366-3372	matter	_	
20-31	3373-3382	integrity	_	
20-32	3383-3384	(	_	
20-33	3384-3392	measured	_	
20-34	3393-3395	by	_	
20-35	3396-3406	fractional	_	
20-36	3407-3417	anisotropy	_	
20-37	3418-3420	or	_	
20-38	3421-3425	mean	_	
20-39	3426-3437	diffusivity	_	
20-40	3437-3438	)	_	
20-41	3438-3439	,	_	
20-42	3440-3443	and	_	
20-43	3444-3451	altered	_	
20-44	3452-3462	functional	_	
20-45	3463-3471	activity	_	
20-46	3472-3477	under	_	
20-47	3478-3485	various	_	
20-48	3486-3491	tasks	_	
20-49	3492-3494	or	_	
20-50	3495-3501	during	_	
20-51	3502-3509	resting	_	
20-52	3510-3515	state	_	
20-53	3515-3516	.	_	

#Text=Changes in the SN may be one of the most important findings among all insular cortex related networks in schizophrenia.
21-1	3517-3524	Changes	_	
21-2	3525-3527	in	_	
21-3	3528-3531	the	_	
21-4	3532-3534	SN	_	
21-5	3535-3538	may	_	
21-6	3539-3541	be	_	
21-7	3542-3545	one	_	
21-8	3546-3548	of	_	
21-9	3549-3552	the	_	
21-10	3553-3557	most	_	
21-11	3558-3567	important	_	
21-12	3568-3576	findings	_	
21-13	3577-3582	among	_	
21-14	3583-3586	all	_	
21-15	3587-3594	insular	_	
21-16	3595-3601	cortex	_	
21-17	3602-3609	related	_	
21-18	3610-3618	networks	_	
21-19	3619-3621	in	_	
21-20	3622-3635	schizophrenia	_	
21-21	3635-3636	.	_	

#Text=Recently, the anterior insular cortex within the SN has been demonstrated to be crucial to modulate DMN /CEN interactions in patients with schizophrenia.
22-1	3637-3645	Recently	_	
22-2	3645-3646	,	_	
22-3	3647-3650	the	_	
22-4	3651-3659	anterior	_	
22-5	3660-3667	insular	_	
22-6	3668-3674	cortex	_	
22-7	3675-3681	within	_	
22-8	3682-3685	the	_	
22-9	3686-3688	SN	_	
22-10	3689-3692	has	_	
22-11	3693-3697	been	_	
22-12	3698-3710	demonstrated	_	
22-13	3711-3713	to	_	
22-14	3714-3716	be	_	
22-15	3717-3724	crucial	_	
22-16	3725-3727	to	_	
22-17	3728-3736	modulate	_	
22-18	3737-3740	DMN	_	
22-19	3741-3742	/	_	
22-20	3742-3745	CEN	_	
22-21	3746-3758	interactions	_	
22-22	3759-3761	in	_	
22-23	3762-3770	patients	_	
22-24	3771-3775	with	_	
22-25	3776-3789	schizophrenia	_	
22-26	3789-3790	.	_	

#Text=Manoliu et al. also found that the dependence of CEN and DMN interactions on SN’s right anterior insular activity is altered in patients with schizophrenia during acute psychosis or psychotic remission.
23-1	3791-3798	Manoliu	_	
23-2	3799-3801	et	_	
23-3	3802-3804	al	_	
23-4	3804-3805	.	_	
23-5	3806-3810	also	_	
23-6	3811-3816	found	_	
23-7	3817-3821	that	_	
23-8	3822-3825	the	_	
23-9	3826-3836	dependence	_	
23-10	3837-3839	of	_	
23-11	3840-3843	CEN	_	
23-12	3844-3847	and	_	
23-13	3848-3851	DMN	_	
23-14	3852-3864	interactions	_	
23-15	3865-3867	on	_	
23-16	3868-3870	SN	_	
23-17	3870-3871	’	_	
23-18	3871-3872	s	_	
23-19	3873-3878	right	_	
23-20	3879-3887	anterior	_	
23-21	3888-3895	insular	_	
23-22	3896-3904	activity	_	
23-23	3905-3907	is	_	
23-24	3908-3915	altered	_	
23-25	3916-3918	in	_	
23-26	3919-3927	patients	_	
23-27	3928-3932	with	_	
23-28	3933-3946	schizophrenia	_	
23-29	3947-3953	during	_	
23-30	3954-3959	acute	_	
23-31	3960-3969	psychosis	_	
23-32	3970-3972	or	_	
23-33	3973-3982	psychotic	_	
23-34	3983-3992	remission	_	
23-35	3992-3993	.	_	

#Text=Furthermore, insular cortical dysfunction might be associated with core symptoms of schizophrenia.
24-1	3994-4005	Furthermore	_	
24-2	4005-4006	,	_	
24-3	4007-4014	insular	_	
24-4	4015-4023	cortical	_	
24-5	4024-4035	dysfunction	_	
24-6	4036-4041	might	_	
24-7	4042-4044	be	_	
24-8	4045-4055	associated	_	
24-9	4056-4060	with	_	
24-10	4061-4065	core	_	
24-11	4066-4074	symptoms	_	
24-12	4075-4077	of	_	
24-13	4078-4091	schizophrenia	_	
24-14	4091-4092	.	_	

#Text=Aberrant salience network activity in the insular and cingulate cortices has been implicated in the development of positive symptoms of schizophrenia such as delusions and hallucinations due to an inappropriate assignment of salience to stimuli that would normally be considered irrelevant.
25-1	4093-4101	Aberrant	_	
25-2	4102-4110	salience	_	
25-3	4111-4118	network	_	
25-4	4119-4127	activity	_	
25-5	4128-4130	in	_	
25-6	4131-4134	the	_	
25-7	4135-4142	insular	_	
25-8	4143-4146	and	_	
25-9	4147-4156	cingulate	_	
25-10	4157-4165	cortices	_	
25-11	4166-4169	has	_	
25-12	4170-4174	been	_	
25-13	4175-4185	implicated	_	
25-14	4186-4188	in	_	
25-15	4189-4192	the	_	
25-16	4193-4204	development	_	
25-17	4205-4207	of	_	
25-18	4208-4216	positive	_	
25-19	4217-4225	symptoms	_	
25-20	4226-4228	of	_	
25-21	4229-4242	schizophrenia	_	
25-22	4243-4247	such	_	
25-23	4248-4250	as	_	
25-24	4251-4260	delusions	_	
25-25	4261-4264	and	_	
25-26	4265-4279	hallucinations	_	
25-27	4280-4283	due	_	
25-28	4284-4286	to	_	
25-29	4287-4289	an	_	
25-30	4290-4303	inappropriate	_	
25-31	4304-4314	assignment	_	
25-32	4315-4317	of	_	
25-33	4318-4326	salience	_	
25-34	4327-4329	to	_	
25-35	4330-4337	stimuli	_	
25-36	4338-4342	that	_	
25-37	4343-4348	would	_	
25-38	4349-4357	normally	_	
25-39	4358-4360	be	_	
25-40	4361-4371	considered	_	
25-41	4372-4382	irrelevant	_	
25-42	4382-4383	.	_	

#Text=Patients with schizophrenia are usually suffer from impaired insight; both awareness and mental state attribution, two core components of insight, are associated with the function of insular cortex.
26-1	4384-4392	Patients	_	
26-2	4393-4397	with	_	
26-3	4398-4411	schizophrenia	_	
26-4	4412-4415	are	_	
26-5	4416-4423	usually	_	
26-6	4424-4430	suffer	_	
26-7	4431-4435	from	_	
26-8	4436-4444	impaired	_	
26-9	4445-4452	insight	_	
26-10	4452-4453	;	_	
26-11	4454-4458	both	_	
26-12	4459-4468	awareness	_	
26-13	4469-4472	and	_	
26-14	4473-4479	mental	_	
26-15	4480-4485	state	_	
26-16	4486-4497	attribution	_	
26-17	4497-4498	,	_	
26-18	4499-4502	two	_	
26-19	4503-4507	core	_	
26-20	4508-4518	components	_	
26-21	4519-4521	of	_	
26-22	4522-4529	insight	_	
26-23	4529-4530	,	_	
26-24	4531-4534	are	_	
26-25	4535-4545	associated	_	
26-26	4546-4550	with	_	
26-27	4551-4554	the	_	
26-28	4555-4563	function	_	
26-29	4564-4566	of	_	
26-30	4567-4574	insular	_	
26-31	4575-4581	cortex	_	
26-32	4581-4582	.	_	

#Text=Previous studies have provided compelling evidence supporting the critical role of insular cortex in schizophrenia.
27-1	4583-4591	Previous	_	
27-2	4592-4599	studies	_	
27-3	4600-4604	have	_	
27-4	4605-4613	provided	_	
27-5	4614-4624	compelling	_	
27-6	4625-4633	evidence	_	
27-7	4634-4644	supporting	_	
27-8	4645-4648	the	_	
27-9	4649-4657	critical	_	
27-10	4658-4662	role	_	
27-11	4663-4665	of	_	
27-12	4666-4673	insular	_	
27-13	4674-4680	cortex	_	
27-14	4681-4683	in	_	
27-15	4684-4697	schizophrenia	_	
27-16	4697-4698	.	_	

#Text=However, most studies examining the functional connectivity between insular cortex and other brain areas were in schizophrenia patients treated with antipsychotics.
28-1	4699-4706	However	_	
28-2	4706-4707	,	_	
28-3	4708-4712	most	_	
28-4	4713-4720	studies	_	
28-5	4721-4730	examining	_	
28-6	4731-4734	the	_	
28-7	4735-4745	functional	_	
28-8	4746-4758	connectivity	_	
28-9	4759-4766	between	_	
28-10	4767-4774	insular	_	
28-11	4775-4781	cortex	_	
28-12	4782-4785	and	_	
28-13	4786-4791	other	_	
28-14	4792-4797	brain	_	
28-15	4798-4803	areas	_	
28-16	4804-4808	were	_	
28-17	4809-4811	in	_	
28-18	4812-4825	schizophrenia	_	
28-19	4826-4834	patients	_	
28-20	4835-4842	treated	_	
28-21	4843-4847	with	_	
28-22	4848-4862	antipsychotics	_	
28-23	4862-4863	.	_	

#Text=The potential confounding effect of antipsychotic treatment on the brain functional connectivity has been well established.
29-1	4864-4867	The	_	
29-2	4868-4877	potential	_	
29-3	4878-4889	confounding	_	
29-4	4890-4896	effect	_	
29-5	4897-4899	of	_	
29-6	4900-4913	antipsychotic	_	
29-7	4914-4923	treatment	_	
29-8	4924-4926	on	_	
29-9	4927-4930	the	_	
29-10	4931-4936	brain	_	
29-11	4937-4947	functional	_	
29-12	4948-4960	connectivity	_	
29-13	4961-4964	has	_	
29-14	4965-4969	been	_	
29-15	4970-4974	well	_	
29-16	4975-4986	established	_	
29-17	4986-4987	.	_	

#Text=The purpose of the present study was to examine the insular cortical functional connectivity and its relationship with the severity of clinical symptoms in drug naïve, first episode schizophrenic patients.
#Text=2.
30-1	4988-4991	The	_	
30-2	4992-4999	purpose	_	
30-3	5000-5002	of	_	
30-4	5003-5006	the	_	
30-5	5007-5014	present	_	
30-6	5015-5020	study	_	
30-7	5021-5024	was	_	
30-8	5025-5027	to	_	
30-9	5028-5035	examine	_	
30-10	5036-5039	the	_	
30-11	5040-5047	insular	_	
30-12	5048-5056	cortical	_	
30-13	5057-5067	functional	_	
30-14	5068-5080	connectivity	_	
30-15	5081-5084	and	_	
30-16	5085-5088	its	_	
30-17	5089-5101	relationship	_	
30-18	5102-5106	with	_	
30-19	5107-5110	the	_	
30-20	5111-5119	severity	_	
30-21	5120-5122	of	_	
30-22	5123-5131	clinical	_	
30-23	5132-5140	symptoms	_	
30-24	5141-5143	in	_	
30-25	5144-5148	drug	_	
30-26	5149-5154	naïve	_	
30-27	5154-5155	,	_	
30-28	5156-5161	first	_	
30-29	5162-5169	episode	_	
30-30	5170-5183	schizophrenic	_	
30-31	5184-5192	patients	_	
30-32	5192-5193	.	_	
30-33	5194-5195	2	_	
30-34	5195-5196	.	_	

#Text=Methods
#Text=2.1.
31-1	5197-5204	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[16]	
31-2	5205-5208	2.1	http://www.case.edu/ProvCaRe/provcare#StudyMethod[16]	
31-3	5208-5209	.	_	

#Text=Subjects
#Text=The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University.
32-1	5210-5218	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-2	5219-5222	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-3	5223-5228	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-4	5229-5232	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-5	5233-5241	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-6	5242-5244	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-7	5245-5248	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-8	5249-5255	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-9	5256-5265	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-10	5266-5268	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-11	5269-5272	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-12	5273-5278	First	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-13	5279-5289	Affiliated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-14	5290-5298	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-15	5299-5301	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-16	5302-5311	Zhengzhou	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-17	5312-5322	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
32-18	5322-5323	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=All subjects provided written informed consent to participate in the study.
33-1	5324-5327	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-2	5328-5336	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-3	5337-5345	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-4	5346-5353	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-5	5354-5362	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-6	5363-5370	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-7	5371-5373	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-8	5374-5385	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-9	5386-5388	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-10	5389-5392	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-11	5393-5398	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
33-12	5398-5399	.	_	

#Text=Subjects were recruited from the consecutive admissions to the inpatient unit between November 2011 and December 2012.
34-1	5400-5408	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-2	5409-5413	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-3	5414-5423	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-4	5424-5428	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-5	5429-5432	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-6	5433-5444	consecutive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-7	5445-5455	admissions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-8	5456-5458	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-9	5459-5462	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-10	5463-5472	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-11	5473-5477	unit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-12	5478-5485	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-13	5486-5494	November	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-14	5495-5499	2011	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-15	5500-5503	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-16	5504-5512	December	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-17	5513-5517	2012	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-18	5517-5518	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Inclusion criteria included: 1) diagnosis of schizophrenia according to the criteria of DSM-IV; 2) 18–45 years old; 3) in the age rangenever treated with antipsychotic medications or other psychotropics.
35-1	5519-5528	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-2	5529-5537	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-3	5538-5546	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-4	5546-5547	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-5	5548-5549	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-6	5549-5550	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-7	5551-5560	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-8	5561-5563	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-9	5564-5577	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-10	5578-5587	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-11	5588-5590	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-12	5591-5594	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-13	5595-5603	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-14	5604-5606	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-15	5607-5613	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-16	5613-5614	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-17	5615-5616	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-18	5616-5617	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-19	5618-5620	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-20	5620-5621	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-21	5621-5623	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-22	5624-5629	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-23	5630-5633	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-24	5633-5634	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-25	5635-5636	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-26	5636-5637	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-27	5638-5640	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-28	5641-5644	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-29	5645-5648	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-30	5649-5659	rangenever	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-31	5660-5667	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-32	5668-5672	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-33	5673-5686	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-34	5687-5698	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-35	5699-5701	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-36	5702-5707	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-37	5708-5721	psychotropics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
35-38	5721-5722	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	

#Text=The diagnosis of schizophrenia was confirmed by a research psychiatrist (X.S.) using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-IV).
36-1	5723-5726	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-2	5727-5736	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-3	5737-5739	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-4	5740-5753	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[21]	
36-5	5754-5757	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-6	5758-5767	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-7	5768-5770	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-8	5771-5772	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-9	5773-5781	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-10	5782-5794	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-11	5795-5796	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-12	5796-5799	X.S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-13	5799-5800	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-14	5800-5801	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-15	5802-5807	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-16	5808-5811	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
36-17	5812-5822	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-18	5823-5831	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-19	5832-5841	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-20	5842-5845	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-21	5846-5852	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-22	5853-5857	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-23	5858-5859	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-24	5860-5869	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]	
36-25	5870-5871	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]|*[23]	
36-26	5871-5878	SCID-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]|*[23]	
36-27	5878-5879	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[22]|*[23]	
36-28	5879-5880	.	_	

#Text=Exclusion criteria were: 1) history of alcohol or other substance use; 2) history of brain injury; 3) any ongoing significant medical conditions.
37-1	5881-5890	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-2	5891-5899	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-3	5900-5904	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-4	5904-5905	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-5	5906-5907	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-6	5907-5908	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-7	5909-5916	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-8	5917-5919	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-9	5920-5927	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-10	5928-5930	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-11	5931-5936	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-12	5937-5946	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-13	5947-5950	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-14	5950-5951	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-15	5952-5953	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-16	5953-5954	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-17	5955-5962	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-18	5963-5965	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-19	5966-5971	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-20	5972-5978	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-21	5978-5979	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-22	5980-5981	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-23	5981-5982	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-24	5983-5986	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-25	5987-5994	ongoing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-26	5995-6006	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-27	6007-6014	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-28	6015-6025	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
37-29	6025-6026	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=Healthy control subjects were recruited from the local community through advertisements.
38-1	6027-6034	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
38-2	6035-6042	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
38-3	6043-6051	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
38-4	6052-6056	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-5	6057-6066	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-6	6067-6071	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-7	6072-6075	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-8	6076-6081	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-9	6082-6091	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-10	6092-6099	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-11	6100-6114	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
38-12	6114-6115	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=The same research psychiatrist (X.S.) conducted a comprehensive clinical interview to rule out any psychiatric conditions in healthy controls.
39-1	6116-6119	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-2	6120-6124	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-3	6125-6133	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-4	6134-6146	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-5	6147-6148	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-6	6148-6151	X.S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-7	6151-6152	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-8	6152-6153	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-9	6154-6163	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-10	6164-6165	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-11	6166-6179	comprehensive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-12	6180-6188	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-13	6189-6198	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-14	6199-6201	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-15	6202-6206	rule	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-16	6207-6210	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-17	6211-6214	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-18	6215-6226	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-19	6227-6237	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-20	6238-6240	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-21	6241-6248	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-22	6249-6257	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
39-23	6257-6258	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=A complete medical history, physical examination, and routine laboratory tests were obtained from all subjects to rule out possible medical conditions.
40-1	6259-6260	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-2	6261-6269	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-3	6270-6277	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-4	6278-6285	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-5	6285-6286	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-6	6287-6295	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-7	6296-6307	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-8	6307-6308	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-9	6309-6312	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-10	6313-6320	routine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-11	6321-6331	laboratory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-12	6332-6337	tests	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-13	6338-6342	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-14	6343-6351	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-15	6352-6356	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-16	6357-6360	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-17	6361-6369	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-18	6370-6372	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-19	6373-6377	rule	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-20	6378-6381	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-21	6382-6390	possible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-22	6391-6398	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-23	6399-6409	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
40-24	6409-6410	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=All subjects were right-handed.
#Text=2.2.
41-1	6411-6414	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
41-2	6415-6423	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
41-3	6424-6428	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
41-4	6429-6441	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
41-5	6441-6442	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]	
41-6	6443-6446	2.2	_	
41-7	6446-6447	.	_	

#Text=Clinical symptom measurement
#Text=Symptoms of schizophrenia were assessed for all patients using the Positive and Negative Syndrome Scale (PANSS), which includes 3 subscales: positive symptoms, negative symptoms and general psychopathology.
42-1	6448-6456	Clinical	_	
42-2	6457-6464	symptom	_	
42-3	6465-6476	measurement	_	
42-4	6477-6485	Symptoms	_	
42-5	6486-6488	of	_	
42-6	6489-6502	schizophrenia	_	
42-7	6503-6507	were	_	
42-8	6508-6516	assessed	_	
42-9	6517-6520	for	_	
42-10	6521-6524	all	_	
42-11	6525-6533	patients	_	
42-12	6534-6539	using	_	
42-13	6540-6543	the	_	
42-14	6544-6552	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
42-15	6553-6556	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
42-16	6557-6565	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
42-17	6566-6574	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
42-18	6575-6580	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
42-19	6581-6582	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
42-20	6582-6587	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[27]	
42-21	6587-6588	)	_	
42-22	6588-6589	,	_	
42-23	6590-6595	which	_	
42-24	6596-6604	includes	_	
42-25	6605-6606	3	_	
42-26	6607-6616	subscales	_	
42-27	6616-6617	:	_	
42-28	6618-6626	positive	_	
42-29	6627-6635	symptoms	_	
42-30	6635-6636	,	_	
42-31	6637-6645	negative	_	
42-32	6646-6654	symptoms	_	
42-33	6655-6658	and	_	
42-34	6659-6666	general	_	
42-35	6667-6682	psychopathology	_	
42-36	6682-6683	.	_	

#Text=The PANSS was administered by the same rater (J.G.) throughout the study.
#Text=2.3.
43-1	6684-6687	The	_	
43-2	6688-6693	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
43-3	6694-6697	was	_	
43-4	6698-6710	administered	_	
43-5	6711-6713	by	_	
43-6	6714-6717	the	_	
43-7	6718-6722	same	_	
43-8	6723-6728	rater	_	
43-9	6729-6730	(	_	
43-10	6730-6733	J.G	_	
43-11	6733-6734	.	_	
43-12	6734-6735	)	_	
43-13	6736-6746	throughout	_	
43-14	6747-6750	the	_	
43-15	6751-6756	study	_	
43-16	6756-6757	.	_	
43-17	6758-6761	2.3	_	
43-18	6761-6762	.	_	

#Text=Image acquisition
#Text=On the same day after clinical assessment and before taking any antipsychotic or other psychotropic medications, all participants were scanned on a 3.0 Tesla Scanner (Signa HDxt 3T GEHCGEHC) at the Magnetic Resonance Center of the First Affiliated Hospital of Zhengzhou University.
44-1	6763-6768	Image	_	
44-2	6769-6780	acquisition	_	
44-3	6781-6783	On	_	
44-4	6784-6787	the	_	
44-5	6788-6792	same	_	
44-6	6793-6796	day	_	
44-7	6797-6802	after	_	
44-8	6803-6811	clinical	_	
44-9	6812-6822	assessment	_	
44-10	6823-6826	and	_	
44-11	6827-6833	before	_	
44-12	6834-6840	taking	_	
44-13	6841-6844	any	_	
44-14	6845-6858	antipsychotic	_	
44-15	6859-6861	or	_	
44-16	6862-6867	other	_	
44-17	6868-6880	psychotropic	_	
44-18	6881-6892	medications	_	
44-19	6892-6893	,	_	
44-20	6894-6897	all	_	
44-21	6898-6910	participants	_	
44-22	6911-6915	were	_	
44-23	6916-6923	scanned	_	
44-24	6924-6926	on	_	
44-25	6927-6928	a	_	
44-26	6929-6932	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-27	6933-6938	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-28	6939-6946	Scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-29	6947-6948	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-30	6948-6953	Signa	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-31	6954-6958	HDxt	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-32	6959-6961	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-33	6962-6970	GEHCGEHC	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-34	6970-6971	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[28]	
44-35	6972-6974	at	_	
44-36	6975-6978	the	_	
44-37	6979-6987	Magnetic	_	
44-38	6988-6997	Resonance	_	
44-39	6998-7004	Center	_	
44-40	7005-7007	of	_	
44-41	7008-7011	the	_	
44-42	7012-7017	First	_	
44-43	7018-7028	Affiliated	_	
44-44	7029-7037	Hospital	_	
44-45	7038-7040	of	_	
44-46	7041-7050	Zhengzhou	_	
44-47	7051-7061	University	_	
44-48	7061-7062	.	_	

#Text=A 6 minute ‘resting-state’ functional MRI scan was obtained, comprising of 180 time points of whole-brain functional (EPI) volumes (TR = 2000 ms; TE = 30ms; flip angle = 90; 34 contiguous AC–PC aligned axial slices; matrix = 64×64; FOV = 22 cm; acquisition voxel size = 3.4mm×3.4mm×4 mm).
45-1	7063-7064	A	_	
45-2	7065-7066	6	_	
45-3	7067-7073	minute	_	
45-4	7074-7075	‘	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]	
45-5	7075-7088	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]	
45-6	7088-7089	’	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]	
45-7	7090-7100	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]	
45-8	7101-7104	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]	
45-9	7105-7109	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[29]	
45-10	7110-7113	was	_	
45-11	7114-7122	obtained	_	
45-12	7122-7123	,	_	
45-13	7124-7134	comprising	_	
45-14	7135-7137	of	_	
45-15	7138-7141	180	_	
45-16	7142-7146	time	_	
45-17	7147-7153	points	_	
45-18	7154-7156	of	_	
45-19	7157-7168	whole-brain	_	
45-20	7169-7179	functional	_	
45-21	7180-7181	(	_	
45-22	7181-7184	EPI	_	
45-23	7184-7185	)	_	
45-24	7186-7193	volumes	_	
45-25	7194-7195	(	_	
45-26	7195-7197	TR	_	
45-27	7198-7199	=	_	
45-28	7200-7204	2000	_	
45-29	7205-7207	ms	_	
45-30	7207-7208	;	_	
45-31	7209-7211	TE	_	
45-32	7212-7213	=	_	
45-33	7214-7218	30ms	_	
45-34	7218-7219	;	_	
45-35	7220-7224	flip	_	
45-36	7225-7230	angle	_	
45-37	7231-7232	=	_	
45-38	7233-7235	90	_	
45-39	7235-7236	;	_	
45-40	7237-7239	34	_	
45-41	7240-7250	contiguous	_	
45-42	7251-7256	AC–PC	_	
45-43	7257-7264	aligned	_	
45-44	7265-7270	axial	_	
45-45	7271-7277	slices	_	
45-46	7277-7278	;	_	
45-47	7279-7285	matrix	_	
45-48	7286-7287	=	_	
45-49	7288-7290	64	_	
45-50	7290-7291	×	_	
45-51	7291-7293	64	_	
45-52	7293-7294	;	_	
45-53	7295-7298	FOV	_	
45-54	7299-7300	=	_	
45-55	7301-7303	22	_	
45-56	7304-7306	cm	_	
45-57	7306-7307	;	_	
45-58	7308-7319	acquisition	_	
45-59	7320-7325	voxel	_	
45-60	7326-7330	size	_	
45-61	7331-7332	=	_	
45-62	7333-7338	3.4mm	_	
45-63	7338-7339	×	_	
45-64	7339-7344	3.4mm	_	
45-65	7344-7345	×	_	
45-66	7345-7346	4	_	
45-67	7347-7349	mm	_	
45-68	7349-7350	)	_	
45-69	7350-7351	.	_	

#Text=During this scan that acquired all neuroimaging data, participants were instructed to rest without moving.
46-1	7352-7358	During	_	
46-2	7359-7363	this	_	
46-3	7364-7368	scan	_	
46-4	7369-7373	that	_	
46-5	7374-7382	acquired	_	
46-6	7383-7386	all	_	
46-7	7387-7399	neuroimaging	_	
46-8	7400-7404	data	_	
46-9	7404-7405	,	_	
46-10	7406-7418	participants	_	
46-11	7419-7423	were	_	
46-12	7424-7434	instructed	_	
46-13	7435-7437	to	_	
46-14	7438-7442	rest	_	
46-15	7443-7450	without	_	
46-16	7451-7457	moving	_	
46-17	7457-7458	.	_	

#Text=The wakefulness of the subject was verified by self-report at the end of the scan.
47-1	7459-7462	The	_	
47-2	7463-7474	wakefulness	_	
47-3	7475-7477	of	_	
47-4	7478-7481	the	_	
47-5	7482-7489	subject	_	
47-6	7490-7493	was	_	
47-7	7494-7502	verified	_	
47-8	7503-7505	by	_	
47-9	7506-7517	self-report	_	
47-10	7518-7520	at	_	
47-11	7521-7524	the	_	
47-12	7525-7528	end	_	
47-13	7529-7531	of	_	
47-14	7532-7535	the	_	
47-15	7536-7540	scan	_	
47-16	7540-7541	.	_	

#Text=T1-weighted Spoiled Gradient Echo (SPGR) images were also collected for the purposes of anatomical localization.
48-1	7542-7544	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[30]	
48-2	7544-7545	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[30]	
48-3	7545-7553	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[30]	
48-4	7554-7561	Spoiled	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[30]	
48-5	7562-7570	Gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[30]	
48-6	7571-7575	Echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[30]	
48-7	7576-7577	(	_	
48-8	7577-7581	SPGR	_	
48-9	7581-7582	)	_	
48-10	7583-7589	images	_	
48-11	7590-7594	were	_	
48-12	7595-7599	also	_	
48-13	7600-7609	collected	_	
48-14	7610-7613	for	_	
48-15	7614-7617	the	_	
48-16	7618-7626	purposes	_	
48-17	7627-7629	of	_	
48-18	7630-7640	anatomical	_	
48-19	7641-7653	localization	_	
48-20	7653-7654	.	_	

#Text=The acquisition protocol included the following pulse sequence and parameters: repetition time (TR) = 12ms, echo time (TE) = 4.5ms, inversion time (TI) = 1100ms, flip angle 7°, field of view (FOV) = 256×256×220 mm3, matrix size 256×256, slice thickness 1mm contiguous, and scan time 17 min.
#Text=2.4.
49-1	7655-7658	The	_	
49-2	7659-7670	acquisition	_	
49-3	7671-7679	protocol	_	
49-4	7680-7688	included	_	
49-5	7689-7692	the	_	
49-6	7693-7702	following	_	
49-7	7703-7708	pulse	_	
49-8	7709-7717	sequence	_	
49-9	7718-7721	and	_	
49-10	7722-7732	parameters	_	
49-11	7732-7733	:	_	
49-12	7734-7744	repetition	_	
49-13	7745-7749	time	_	
49-14	7750-7751	(	_	
49-15	7751-7753	TR	_	
49-16	7753-7754	)	_	
49-17	7755-7756	=	_	
49-18	7757-7761	12ms	_	
49-19	7761-7762	,	_	
49-20	7763-7767	echo	_	
49-21	7768-7772	time	_	
49-22	7773-7774	(	_	
49-23	7774-7776	TE	_	
49-24	7776-7777	)	_	
49-25	7778-7779	=	_	
49-26	7780-7785	4.5ms	_	
49-27	7785-7786	,	_	
49-28	7787-7796	inversion	_	
49-29	7797-7801	time	_	
49-30	7802-7803	(	_	
49-31	7803-7805	TI	_	
49-32	7805-7806	)	_	
49-33	7807-7808	=	_	
49-34	7809-7815	1100ms	_	
49-35	7815-7816	,	_	
49-36	7817-7821	flip	_	
49-37	7822-7827	angle	_	
49-38	7828-7829	7	_	
49-39	7829-7830	°	_	
49-40	7830-7831	,	_	
49-41	7832-7837	field	_	
49-42	7838-7840	of	_	
49-43	7841-7845	view	_	
49-44	7846-7847	(	_	
49-45	7847-7850	FOV	_	
49-46	7850-7851	)	_	
49-47	7852-7853	=	_	
49-48	7854-7857	256	_	
49-49	7857-7858	×	_	
49-50	7858-7861	256	_	
49-51	7861-7862	×	_	
49-52	7862-7865	220	_	
49-53	7866-7869	mm3	_	
49-54	7869-7870	,	_	
49-55	7871-7877	matrix	_	
49-56	7878-7882	size	_	
49-57	7883-7886	256	_	
49-58	7886-7887	×	_	
49-59	7887-7890	256	_	
49-60	7890-7891	,	_	
49-61	7892-7897	slice	_	
49-62	7898-7907	thickness	_	
49-63	7908-7911	1mm	_	
49-64	7912-7922	contiguous	_	
49-65	7922-7923	,	_	
49-66	7924-7927	and	_	
49-67	7928-7932	scan	_	
49-68	7933-7937	time	_	
49-69	7938-7940	17	_	
49-70	7941-7944	min	_	
49-71	7944-7945	.	_	
49-72	7946-7949	2.4	_	
49-73	7949-7950	.	_	

#Text=Image processing
#Text=Imaging data were coded and catalogued before being transferred to the Psychotic Disorders Program of the University of Massachusetts Medical School (UMMS) for blinded analysis.
50-1	7951-7956	Image	_	
50-2	7957-7967	processing	_	
50-3	7968-7975	Imaging	_	
50-4	7976-7980	data	_	
50-5	7981-7985	were	_	
50-6	7986-7991	coded	_	
50-7	7992-7995	and	_	
50-8	7996-8006	catalogued	_	
50-9	8007-8013	before	_	
50-10	8014-8019	being	_	
50-11	8020-8031	transferred	_	
50-12	8032-8034	to	_	
50-13	8035-8038	the	_	
50-14	8039-8048	Psychotic	_	
50-15	8049-8058	Disorders	_	
50-16	8059-8066	Program	_	
50-17	8067-8069	of	_	
50-18	8070-8073	the	_	
50-19	8074-8084	University	_	
50-20	8085-8087	of	_	
50-21	8088-8101	Massachusetts	_	
50-22	8102-8109	Medical	_	
50-23	8110-8116	School	_	
50-24	8117-8118	(	_	
50-25	8118-8122	UMMS	_	
50-26	8122-8123	)	_	
50-27	8124-8127	for	_	
50-28	8128-8135	blinded	_	
50-29	8136-8144	analysis	_	
50-30	8144-8145	.	_	

#Text=AFNI was used for image preprocessing (http://www.afni.nimh.gov/afni), performing slice timing correction for interleaved acquisition (using Fourier interpolation), motion correction (by aligning each volume to a “base” image [middle volume] using Fourier interpolation) and de-spiking (detection and reduction of extreme time series outliers using a hyperbolic tangent function).
51-1	8146-8150	AFNI	_	
51-2	8151-8154	was	_	
51-3	8155-8159	used	_	
51-4	8160-8163	for	_	
51-5	8164-8169	image	_	
51-6	8170-8183	preprocessing	_	
51-7	8184-8185	(	_	
51-8	8185-8189	http	_	
51-9	8189-8190	:	_	
51-10	8190-8191	/	_	
51-11	8191-8192	/	_	
51-12	8192-8209	www.afni.nimh.gov	_	
51-13	8209-8210	/	_	
51-14	8210-8214	afni	_	
51-15	8214-8215	)	_	
51-16	8215-8216	,	_	
51-17	8217-8227	performing	_	
51-18	8228-8233	slice	_	
51-19	8234-8240	timing	_	
51-20	8241-8251	correction	_	
51-21	8252-8255	for	_	
51-22	8256-8267	interleaved	_	
51-23	8268-8279	acquisition	_	
51-24	8280-8281	(	_	
51-25	8281-8286	using	_	
51-26	8287-8294	Fourier	_	
51-27	8295-8308	interpolation	_	
51-28	8308-8309	)	_	
51-29	8309-8310	,	_	
51-30	8311-8317	motion	_	
51-31	8318-8328	correction	_	
51-32	8329-8330	(	_	
51-33	8330-8332	by	_	
51-34	8333-8341	aligning	_	
51-35	8342-8346	each	_	
51-36	8347-8353	volume	_	
51-37	8354-8356	to	_	
51-38	8357-8358	a	_	
51-39	8359-8360	“	_	
51-40	8360-8364	base	_	
51-41	8364-8365	”	_	
51-42	8366-8371	image	_	
51-43	8372-8373	[	_	
51-44	8373-8379	middle	_	
51-45	8380-8386	volume	_	
51-46	8386-8387	]	_	
51-47	8388-8393	using	_	
51-48	8394-8401	Fourier	_	
51-49	8402-8415	interpolation	_	
51-50	8415-8416	)	_	
51-51	8417-8420	and	_	
51-52	8421-8431	de-spiking	_	
51-53	8432-8433	(	_	
51-54	8433-8442	detection	_	
51-55	8443-8446	and	_	
51-56	8447-8456	reduction	_	
51-57	8457-8459	of	_	
51-58	8460-8467	extreme	_	
51-59	8468-8472	time	_	
51-60	8473-8479	series	_	
51-61	8480-8488	outliers	_	
51-62	8489-8494	using	_	
51-63	8495-8496	a	_	
51-64	8497-8507	hyperbolic	_	
51-65	8508-8515	tangent	_	
51-66	8516-8524	function	_	
51-67	8524-8525	)	_	
51-68	8525-8526	.	_	

#Text=All other data processing was carried out using FMRIB Software Library (FSL) (http://www.fmrib.ox.ac.uk), including spatial smoothing (FWHM = 6 mm), mean-based intensity normalization of all volumes, temporal bandpass filtering (highpass temporal filtering: Gaussian-weighted least-squares straight line fitting, with sigma = 100.0 s; Gaussian lowpass temporal filtering HWHM 2.8 s), and pre-whitening.
52-1	8527-8530	All	_	
52-2	8531-8536	other	_	
52-3	8537-8541	data	_	
52-4	8542-8552	processing	_	
52-5	8553-8556	was	_	
52-6	8557-8564	carried	_	
52-7	8565-8568	out	_	
52-8	8569-8574	using	_	
52-9	8575-8580	FMRIB	_	
52-10	8581-8589	Software	_	
52-11	8590-8597	Library	_	
52-12	8598-8599	(	_	
52-13	8599-8602	FSL	_	
52-14	8602-8603	)	_	
52-15	8604-8605	(	_	
52-16	8605-8609	http	_	
52-17	8609-8610	:	_	
52-18	8610-8611	/	_	
52-19	8611-8612	/	_	
52-20	8612-8630	www.fmrib.ox.ac.uk	_	
52-21	8630-8631	)	_	
52-22	8631-8632	,	_	
52-23	8633-8642	including	_	
52-24	8643-8650	spatial	_	
52-25	8651-8660	smoothing	_	
52-26	8661-8662	(	_	
52-27	8662-8666	FWHM	_	
52-28	8667-8668	=	_	
52-29	8669-8670	6	_	
52-30	8671-8673	mm	_	
52-31	8673-8674	)	_	
52-32	8674-8675	,	_	
52-33	8676-8686	mean-based	_	
52-34	8687-8696	intensity	_	
52-35	8697-8710	normalization	_	
52-36	8711-8713	of	_	
52-37	8714-8717	all	_	
52-38	8718-8725	volumes	_	
52-39	8725-8726	,	_	
52-40	8727-8735	temporal	_	
52-41	8736-8744	bandpass	_	
52-42	8745-8754	filtering	_	
52-43	8755-8756	(	_	
52-44	8756-8764	highpass	_	
52-45	8765-8773	temporal	_	
52-46	8774-8783	filtering	_	
52-47	8783-8784	:	_	
52-48	8785-8802	Gaussian-weighted	_	
52-49	8803-8816	least-squares	_	
52-50	8817-8825	straight	_	
52-51	8826-8830	line	_	
52-52	8831-8838	fitting	_	
52-53	8838-8839	,	_	
52-54	8840-8844	with	_	
52-55	8845-8850	sigma	_	
52-56	8851-8852	=	_	
52-57	8853-8858	100.0	_	
52-58	8859-8860	s	_	
52-59	8860-8861	;	_	
52-60	8862-8870	Gaussian	_	
52-61	8871-8878	lowpass	_	
52-62	8879-8887	temporal	_	
52-63	8888-8897	filtering	_	
52-64	8898-8902	HWHM	_	
52-65	8903-8906	2.8	_	
52-66	8907-8908	s	_	
52-67	8908-8909	)	_	
52-68	8909-8910	,	_	
52-69	8911-8914	and	_	
52-70	8915-8928	pre-whitening	_	
52-71	8928-8929	.	_	

#Text=Each individual’s time series were spatially normalized by registration to the MNI152 (Montreal Neurological Institute) template with 2mm3 resolution, using a 12 degree of freedom affine transformation.
53-1	8930-8934	Each	_	
53-2	8935-8945	individual	_	
53-3	8945-8946	’	_	
53-4	8946-8947	s	_	
53-5	8948-8952	time	_	
53-6	8953-8959	series	_	
53-7	8960-8964	were	_	
53-8	8965-8974	spatially	_	
53-9	8975-8985	normalized	_	
53-10	8986-8988	by	_	
53-11	8989-9001	registration	_	
53-12	9002-9004	to	_	
53-13	9005-9008	the	_	
53-14	9009-9015	MNI152	_	
53-15	9016-9017	(	_	
53-16	9017-9025	Montreal	_	
53-17	9026-9038	Neurological	_	
53-18	9039-9048	Institute	_	
53-19	9048-9049	)	_	
53-20	9050-9058	template	_	
53-21	9059-9063	with	_	
53-22	9064-9068	2mm3	_	
53-23	9069-9079	resolution	_	
53-24	9079-9080	,	_	
53-25	9081-9086	using	_	
53-26	9087-9088	a	_	
53-27	9089-9091	12	_	
53-28	9092-9098	degree	_	
53-29	9099-9101	of	_	
53-30	9102-9109	freedom	_	
53-31	9110-9116	affine	_	
53-32	9117-9131	transformation	_	
53-33	9131-9132	.	_	

#Text=Nine nuisance covariates (time series for global signal intensity, white matter, cerebrospinal fluid, and six motion parameters) were regressed out of the data to minimize the contributions of artifactual physiological signals (e.g., cardiac and respiratory cycles) using the general linear model implemented in FSL program FEAT.
54-1	9133-9137	Nine	_	
54-2	9138-9146	nuisance	_	
54-3	9147-9157	covariates	_	
54-4	9158-9159	(	_	
54-5	9159-9163	time	_	
54-6	9164-9170	series	_	
54-7	9171-9174	for	_	
54-8	9175-9181	global	_	
54-9	9182-9188	signal	_	
54-10	9189-9198	intensity	_	
54-11	9198-9199	,	_	
54-12	9200-9205	white	_	
54-13	9206-9212	matter	_	
54-14	9212-9213	,	_	
54-15	9214-9227	cerebrospinal	_	
54-16	9228-9233	fluid	_	
54-17	9233-9234	,	_	
54-18	9235-9238	and	_	
54-19	9239-9242	six	_	
54-20	9243-9249	motion	_	
54-21	9250-9260	parameters	_	
54-22	9260-9261	)	_	
54-23	9262-9266	were	_	
54-24	9267-9276	regressed	_	
54-25	9277-9280	out	_	
54-26	9281-9283	of	_	
54-27	9284-9287	the	_	
54-28	9288-9292	data	_	
54-29	9293-9295	to	_	
54-30	9296-9304	minimize	_	
54-31	9305-9308	the	_	
54-32	9309-9322	contributions	_	
54-33	9323-9325	of	_	
54-34	9326-9337	artifactual	_	
54-35	9338-9351	physiological	_	
54-36	9352-9359	signals	_	
54-37	9360-9361	(	_	
54-38	9361-9364	e.g	_	
54-39	9364-9365	.	_	
54-40	9365-9366	,	_	
54-41	9367-9374	cardiac	_	
54-42	9375-9378	and	_	
54-43	9379-9390	respiratory	_	
54-44	9391-9397	cycles	_	
54-45	9397-9398	)	_	
54-46	9399-9404	using	_	
54-47	9405-9408	the	_	
54-48	9409-9416	general	_	
54-49	9417-9423	linear	_	
54-50	9424-9429	model	_	
54-51	9430-9441	implemented	_	
54-52	9442-9444	in	_	
54-53	9445-9448	FSL	_	
54-54	9449-9456	program	_	
54-55	9457-9461	FEAT	_	
54-56	9461-9462	.	_	

#Text=The FreeSurfer software (http://surfer.nmr.mgh.harvard.edu/) was used to segment T1-weighted SPGR images into cortical and subcortical gray and white matter regions, as well as total intracranial volume, for each subject.
55-1	9463-9466	The	_	
55-2	9467-9477	FreeSurfer	_	
55-3	9478-9486	software	_	
55-4	9487-9488	(	_	
55-5	9488-9492	http	_	
55-6	9492-9493	:	_	
55-7	9493-9494	/	_	
55-8	9494-9495	/	_	
55-9	9495-9521	surfer.nmr.mgh.harvard.edu	_	
55-10	9521-9522	/	_	
55-11	9522-9523	)	_	
55-12	9524-9527	was	_	
55-13	9528-9532	used	_	
55-14	9533-9535	to	_	
55-15	9536-9543	segment	_	
55-16	9544-9546	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
55-17	9546-9547	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
55-18	9547-9555	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
55-19	9556-9560	SPGR	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
55-20	9561-9567	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
55-21	9568-9572	into	_	
55-22	9573-9581	cortical	_	
55-23	9582-9585	and	_	
55-24	9586-9597	subcortical	_	
55-25	9598-9602	gray	_	
55-26	9603-9606	and	_	
55-27	9607-9612	white	_	
55-28	9613-9619	matter	_	
55-29	9620-9627	regions	_	
55-30	9627-9628	,	_	
55-31	9629-9631	as	_	
55-32	9632-9636	well	_	
55-33	9637-9639	as	_	
55-34	9640-9645	total	_	
55-35	9646-9658	intracranial	_	
55-36	9659-9665	volume	_	
55-37	9665-9666	,	_	
55-38	9667-9670	for	_	
55-39	9671-9675	each	_	
55-40	9676-9683	subject	_	
55-41	9683-9684	.	_	

#Text=Functional connectivity was examined using a seed-based approach.
56-1	9685-9695	Functional	_	
56-2	9696-9708	connectivity	_	
56-3	9709-9712	was	_	
56-4	9713-9721	examined	_	
56-5	9722-9727	using	_	
56-6	9728-9729	a	_	
56-7	9730-9740	seed-based	_	
56-8	9741-9749	approach	_	
56-9	9749-9750	.	_	

#Text=The left and right insular seed regions were generated using the Harvard-Oxford atlas, co-localized to the MNI space used in this study.
57-1	9751-9754	The	_	
57-2	9755-9759	left	_	
57-3	9760-9763	and	_	
57-4	9764-9769	right	_	
57-5	9770-9777	insular	_	
57-6	9778-9782	seed	_	
57-7	9783-9790	regions	_	
57-8	9791-9795	were	_	
57-9	9796-9805	generated	_	
57-10	9806-9811	using	_	
57-11	9812-9815	the	_	
57-12	9816-9830	Harvard-Oxford	_	
57-13	9831-9836	atlas	_	
57-14	9836-9837	,	_	
57-15	9838-9850	co-localized	_	
57-16	9851-9853	to	_	
57-17	9854-9857	the	_	
57-18	9858-9861	MNI	_	
57-19	9862-9867	space	_	
57-20	9868-9872	used	_	
57-21	9873-9875	in	_	
57-22	9876-9880	this	_	
57-23	9881-9886	study	_	
57-24	9886-9887	.	_	

#Text=For each participant, we calculated the mean time series of each seed by averaging across all voxels within the seed.
58-1	9888-9891	For	_	
58-2	9892-9896	each	_	
58-3	9897-9908	participant	_	
58-4	9908-9909	,	_	
58-5	9910-9912	we	_	
58-6	9913-9923	calculated	_	
58-7	9924-9927	the	_	
58-8	9928-9932	mean	_	
58-9	9933-9937	time	_	
58-10	9938-9944	series	_	
58-11	9945-9947	of	_	
58-12	9948-9952	each	_	
58-13	9953-9957	seed	_	
58-14	9958-9960	by	_	
58-15	9961-9970	averaging	_	
58-16	9971-9977	across	_	
58-17	9978-9981	all	_	
58-18	9982-9988	voxels	_	
58-19	9989-9995	within	_	
58-20	9996-9999	the	_	
58-21	10000-10004	seed	_	
58-22	10004-10005	.	_	

#Text=A voxel-wise correlation map was generated to each of these seed-based time course reference signals.
59-1	10006-10007	A	_	
59-2	10008-10018	voxel-wise	_	
59-3	10019-10030	correlation	_	
59-4	10031-10034	map	_	
59-5	10035-10038	was	_	
59-6	10039-10048	generated	_	
59-7	10049-10051	to	_	
59-8	10052-10056	each	_	
59-9	10057-10059	of	_	
59-10	10060-10065	these	_	
59-11	10066-10076	seed-based	_	
59-12	10077-10081	time	_	
59-13	10082-10088	course	_	
59-14	10089-10098	reference	_	
59-15	10099-10106	signals	_	
59-16	10106-10107	.	_	

#Text=This correlation map was r-to-Z transformed in order to generate a standardized representation.
60-1	10108-10112	This	_	
60-2	10113-10124	correlation	_	
60-3	10125-10128	map	_	
60-4	10129-10132	was	_	
60-5	10133-10139	r-to-Z	_	
60-6	10140-10151	transformed	_	
60-7	10152-10154	in	_	
60-8	10155-10160	order	_	
60-9	10161-10163	to	_	
60-10	10164-10172	generate	_	
60-11	10173-10174	a	_	
60-12	10175-10187	standardized	_	
60-13	10188-10202	representation	_	
60-14	10202-10203	.	_	

#Text=Each of the remaining cortical and subcortical gray matter regions of the Harvard-Oxford atlas were then used as a mask to determine the average resting state correlation (Z-score) between the insular cortex and each ipsilateral gray matter region in each subject.
#Text=2.5.
61-1	10204-10208	Each	_	
61-2	10209-10211	of	_	
61-3	10212-10215	the	_	
61-4	10216-10225	remaining	_	
61-5	10226-10234	cortical	_	
61-6	10235-10238	and	_	
61-7	10239-10250	subcortical	_	
61-8	10251-10255	gray	_	
61-9	10256-10262	matter	_	
61-10	10263-10270	regions	_	
61-11	10271-10273	of	_	
61-12	10274-10277	the	_	
61-13	10278-10292	Harvard-Oxford	_	
61-14	10293-10298	atlas	_	
61-15	10299-10303	were	_	
61-16	10304-10308	then	_	
61-17	10309-10313	used	_	
61-18	10314-10316	as	_	
61-19	10317-10318	a	_	
61-20	10319-10323	mask	_	
61-21	10324-10326	to	_	
61-22	10327-10336	determine	_	
61-23	10337-10340	the	_	
61-24	10341-10348	average	_	
61-25	10349-10356	resting	_	
61-26	10357-10362	state	_	
61-27	10363-10374	correlation	_	
61-28	10375-10376	(	_	
61-29	10376-10383	Z-score	_	
61-30	10383-10384	)	_	
61-31	10385-10392	between	_	
61-32	10393-10396	the	_	
61-33	10397-10404	insular	_	
61-34	10405-10411	cortex	_	
61-35	10412-10415	and	_	
61-36	10416-10420	each	_	
61-37	10421-10432	ipsilateral	_	
61-38	10433-10437	gray	_	
61-39	10438-10444	matter	_	
61-40	10445-10451	region	_	
61-41	10452-10454	in	_	
61-42	10455-10459	each	_	
61-43	10460-10467	subject	_	
61-44	10467-10468	.	_	
61-45	10469-10472	2.5	_	
61-46	10472-10473	.	_	

#Text=Statistical analysis
#Text=The data were analyzed using SPSS 20.0 (SPSS Inc., Chicago, IL).
62-1	10474-10485	Statistical	_	
62-2	10486-10494	analysis	_	
62-3	10495-10498	The	_	
62-4	10499-10503	data	_	
62-5	10504-10508	were	_	
62-6	10509-10517	analyzed	_	
62-7	10518-10523	using	_	
62-8	10524-10528	SPSS	_	
62-9	10529-10533	20.0	_	
62-10	10534-10535	(	_	
62-11	10535-10539	SPSS	_	
62-12	10540-10543	Inc	_	
62-13	10543-10544	.	_	
62-14	10544-10545	,	_	
62-15	10546-10553	Chicago	_	
62-16	10553-10554	,	_	
62-17	10555-10557	IL	_	
62-18	10557-10558	)	_	
62-19	10558-10559	.	_	

#Text=Demographic and clinical characteristics were reported using descriptive statistics.
63-1	10560-10571	Demographic	_	
63-2	10572-10575	and	_	
63-3	10576-10584	clinical	_	
63-4	10585-10600	characteristics	_	
63-5	10601-10605	were	_	
63-6	10606-10614	reported	_	
63-7	10615-10620	using	_	
63-8	10621-10632	descriptive	_	
63-9	10633-10643	statistics	_	
63-10	10643-10644	.	_	

#Text=The Shapiro-Wilk test was used to check the normality of the data.
64-1	10645-10648	The	_	
64-2	10649-10661	Shapiro-Wilk	_	
64-3	10662-10666	test	_	
64-4	10667-10670	was	_	
64-5	10671-10675	used	_	
64-6	10676-10678	to	_	
64-7	10679-10684	check	_	
64-8	10685-10688	the	_	
64-9	10689-10698	normality	_	
64-10	10699-10701	of	_	
64-11	10702-10705	the	_	
64-12	10706-10710	data	_	
64-13	10710-10711	.	_	

#Text=Group comparisons were performed using the independent samples t-test for continuous variables and Chi-square or Fisher’s exact test for categorical variables.
65-1	10712-10717	Group	_	
65-2	10718-10729	comparisons	_	
65-3	10730-10734	were	_	
65-4	10735-10744	performed	_	
65-5	10745-10750	using	_	
65-6	10751-10754	the	_	
65-7	10755-10766	independent	_	
65-8	10767-10774	samples	_	
65-9	10775-10781	t-test	_	
65-10	10782-10785	for	_	
65-11	10786-10796	continuous	_	
65-12	10797-10806	variables	_	
65-13	10807-10810	and	_	
65-14	10811-10821	Chi-square	_	
65-15	10822-10824	or	_	
65-16	10825-10831	Fisher	_	
65-17	10831-10832	’	_	
65-18	10832-10833	s	_	
65-19	10834-10839	exact	_	
65-20	10840-10844	test	_	
65-21	10845-10848	for	_	
65-22	10849-10860	categorical	_	
65-23	10861-10870	variables	_	
65-24	10870-10871	.	_	

#Text=Connectivity values (Z-scores) of the insular cortex with ipsilateral cortical ROIs were extracted for group comparison, using the independent samples t-test.
66-1	10872-10884	Connectivity	_	
66-2	10885-10891	values	_	
66-3	10892-10893	(	_	
66-4	10893-10901	Z-scores	_	
66-5	10901-10902	)	_	
66-6	10903-10905	of	_	
66-7	10906-10909	the	_	
66-8	10910-10917	insular	_	
66-9	10918-10924	cortex	_	
66-10	10925-10929	with	_	
66-11	10930-10941	ipsilateral	_	
66-12	10942-10950	cortical	_	
66-13	10951-10955	ROIs	_	
66-14	10956-10960	were	_	
66-15	10961-10970	extracted	_	
66-16	10971-10974	for	_	
66-17	10975-10980	group	_	
66-18	10981-10991	comparison	_	
66-19	10991-10992	,	_	
66-20	10993-10998	using	_	
66-21	10999-11002	the	_	
66-22	11003-11014	independent	_	
66-23	11015-11022	samples	_	
66-24	11023-11029	t-test	_	
66-25	11029-11030	.	_	

#Text=Bonferroni corrections considering the number of ROIs were used to define the significance level: p<0.05/48 = 0.001.
67-1	11031-11041	Bonferroni	_	
67-2	11042-11053	corrections	_	
67-3	11054-11065	considering	_	
67-4	11066-11069	the	_	
67-5	11070-11076	number	_	
67-6	11077-11079	of	_	
67-7	11080-11084	ROIs	_	
67-8	11085-11089	were	_	
67-9	11090-11094	used	_	
67-10	11095-11097	to	_	
67-11	11098-11104	define	_	
67-12	11105-11108	the	_	
67-13	11109-11121	significance	_	
67-14	11122-11127	level	_	
67-15	11127-11128	:	_	
67-16	11129-11130	p	_	
67-17	11130-11131	<	_	
67-18	11131-11135	0.05	_	
67-19	11135-11136	/	_	
67-20	11136-11138	48	_	
67-21	11139-11140	=	_	
67-22	11141-11146	0.001	_	
67-23	11146-11147	.	_	

#Text=Insula connectivity maps (Z-score maps) were subjected to voxel-based morphometry (VBM) analysis.
68-1	11148-11154	Insula	_	
68-2	11155-11167	connectivity	_	
68-3	11168-11172	maps	_	
68-4	11173-11174	(	_	
68-5	11174-11181	Z-score	_	
68-6	11182-11186	maps	_	
68-7	11186-11187	)	_	
68-8	11188-11192	were	_	
68-9	11193-11202	subjected	_	
68-10	11203-11205	to	_	
68-11	11206-11217	voxel-based	_	
68-12	11218-11229	morphometry	_	
68-13	11230-11231	(	_	
68-14	11231-11234	VBM	_	
68-15	11234-11235	)	_	
68-16	11236-11244	analysis	_	
68-17	11244-11245	.	_	

#Text=To further explore the regions that show group difference in insular connectivity.
69-1	11246-11248	To	_	
69-2	11249-11256	further	_	
69-3	11257-11264	explore	_	
69-4	11265-11268	the	_	
69-5	11269-11276	regions	_	
69-6	11277-11281	that	_	
69-7	11282-11286	show	_	
69-8	11287-11292	group	_	
69-9	11293-11303	difference	_	
69-10	11304-11306	in	_	
69-11	11307-11314	insular	_	
69-12	11315-11327	connectivity	_	
69-13	11327-11328	.	_	

#Text=A false discovery rate (FDR) corrected p<0.05 was used to define the overall significant level.
70-1	11329-11330	A	_	
70-2	11331-11336	false	_	
70-3	11337-11346	discovery	_	
70-4	11347-11351	rate	_	
70-5	11352-11353	(	_	
70-6	11353-11356	FDR	_	
70-7	11356-11357	)	_	
70-8	11358-11367	corrected	_	
70-9	11368-11369	p	_	
70-10	11369-11370	<	_	
70-11	11370-11374	0.05	_	
70-12	11375-11378	was	_	
70-13	11379-11383	used	_	
70-14	11384-11386	to	_	
70-15	11387-11393	define	_	
70-16	11394-11397	the	_	
70-17	11398-11405	overall	_	
70-18	11406-11417	significant	_	
70-19	11418-11423	level	_	
70-20	11423-11424	.	_	

#Text=Peasson correlation analysis was used to examine the relationship beteween insular connectivity and clinical symptoms as measured by the PANSS; the significance level was set at p<0.05.
#Text=3.
71-1	11425-11432	Peasson	_	
71-2	11433-11444	correlation	_	
71-3	11445-11453	analysis	_	
71-4	11454-11457	was	_	
71-5	11458-11462	used	_	
71-6	11463-11465	to	_	
71-7	11466-11473	examine	_	
71-8	11474-11477	the	_	
71-9	11478-11490	relationship	_	
71-10	11491-11499	beteween	_	
71-11	11500-11507	insular	_	
71-12	11508-11520	connectivity	_	
71-13	11521-11524	and	_	
71-14	11525-11533	clinical	_	
71-15	11534-11542	symptoms	_	
71-16	11543-11545	as	_	
71-17	11546-11554	measured	_	
71-18	11555-11557	by	_	
71-19	11558-11561	the	_	
71-20	11562-11567	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
71-21	11567-11568	;	_	
71-22	11569-11572	the	_	
71-23	11573-11585	significance	_	
71-24	11586-11591	level	_	
71-25	11592-11595	was	_	
71-26	11596-11599	set	_	
71-27	11600-11602	at	_	
71-28	11603-11604	p	_	
71-29	11604-11605	<	_	
71-30	11605-11609	0.05	_	
71-31	11609-11610	.	_	
71-32	11611-11612	3	_	
71-33	11612-11613	.	_	

#Text=Results
#Text=The original study sample included 46 patients with schizophrenia (SZ) and 30 healthy control (HC) subjects.
72-1	11614-11621	Results	_	
72-2	11622-11625	The	_	
72-3	11626-11634	original	_	
72-4	11635-11640	study	_	
72-5	11641-11647	sample	_	
72-6	11648-11656	included	_	
72-7	11657-11659	46	_	
72-8	11660-11668	patients	_	
72-9	11669-11673	with	_	
72-10	11674-11687	schizophrenia	_	
72-11	11688-11689	(	_	
72-12	11689-11691	SZ	_	
72-13	11691-11692	)	_	
72-14	11693-11696	and	_	
72-15	11697-11699	30	_	
72-16	11700-11707	healthy	_	
72-17	11708-11715	control	_	
72-18	11716-11717	(	_	
72-19	11717-11719	HC	_	
72-20	11719-11720	)	_	
72-21	11721-11729	subjects	_	
72-22	11729-11730	.	_	

#Text=One SZ and 2 HC individuals were excluded due to the poor quality of their T1 scans; one SZ and 1 HC individuals were excluded due to the poor quality (missing time series) of the resting-state scans; Seven SZ and 2 HC individuals were excluded because the imaging values were defined as outliers using the criteria of Mean±2SD.
73-1	11731-11734	One	_	
73-2	11735-11737	SZ	_	
73-3	11738-11741	and	_	
73-4	11742-11743	2	_	
73-5	11744-11746	HC	_	
73-6	11747-11758	individuals	_	
73-7	11759-11763	were	_	
73-8	11764-11772	excluded	_	
73-9	11773-11776	due	_	
73-10	11777-11779	to	_	
73-11	11780-11783	the	_	
73-12	11784-11788	poor	_	
73-13	11789-11796	quality	_	
73-14	11797-11799	of	_	
73-15	11800-11805	their	_	
73-16	11806-11808	T1	_	
73-17	11809-11814	scans	_	
73-18	11814-11815	;	_	
73-19	11816-11819	one	_	
73-20	11820-11822	SZ	_	
73-21	11823-11826	and	_	
73-22	11827-11828	1	_	
73-23	11829-11831	HC	_	
73-24	11832-11843	individuals	_	
73-25	11844-11848	were	_	
73-26	11849-11857	excluded	_	
73-27	11858-11861	due	_	
73-28	11862-11864	to	_	
73-29	11865-11868	the	_	
73-30	11869-11873	poor	_	
73-31	11874-11881	quality	_	
73-32	11882-11883	(	_	
73-33	11883-11890	missing	_	
73-34	11891-11895	time	_	
73-35	11896-11902	series	_	
73-36	11902-11903	)	_	
73-37	11904-11906	of	_	
73-38	11907-11910	the	_	
73-39	11911-11924	resting-state	_	
73-40	11925-11930	scans	_	
73-41	11930-11931	;	_	
73-42	11932-11937	Seven	_	
73-43	11938-11940	SZ	_	
73-44	11941-11944	and	_	
73-45	11945-11946	2	_	
73-46	11947-11949	HC	_	
73-47	11950-11961	individuals	_	
73-48	11962-11966	were	_	
73-49	11967-11975	excluded	_	
73-50	11976-11983	because	_	
73-51	11984-11987	the	_	
73-52	11988-11995	imaging	_	
73-53	11996-12002	values	_	
73-54	12003-12007	were	_	
73-55	12008-12015	defined	_	
73-56	12016-12018	as	_	
73-57	12019-12027	outliers	_	
73-58	12028-12033	using	_	
73-59	12034-12037	the	_	
73-60	12038-12046	criteria	_	
73-61	12047-12049	of	_	
73-62	12050-12054	Mean	_	
73-63	12054-12055	±	_	
73-64	12055-12058	2SD	_	
73-65	12058-12059	.	_	

#Text=The final study sample used for data analysis was thus composed of 37 SZ subjects and 25 HC subjects.
74-1	12060-12063	The	_	
74-2	12064-12069	final	_	
74-3	12070-12075	study	_	
74-4	12076-12082	sample	_	
74-5	12083-12087	used	_	
74-6	12088-12091	for	_	
74-7	12092-12096	data	_	
74-8	12097-12105	analysis	_	
74-9	12106-12109	was	_	
74-10	12110-12114	thus	_	
74-11	12115-12123	composed	_	
74-12	12124-12126	of	_	
74-13	12127-12129	37	_	
74-14	12130-12132	SZ	_	
74-15	12133-12141	subjects	_	
74-16	12142-12145	and	_	
74-17	12146-12148	25	_	
74-18	12149-12151	HC	_	
74-19	12152-12160	subjects	_	
74-20	12160-12161	.	_	

#Text=Table 1 shows demographic and clinical characteristics of the study sample.
75-1	12162-12167	Table	_	
75-2	12168-12169	1	_	
75-3	12170-12175	shows	_	
75-4	12176-12187	demographic	_	
75-5	12188-12191	and	_	
75-6	12192-12200	clinical	_	
75-7	12201-12216	characteristics	_	
75-8	12217-12219	of	_	
75-9	12220-12223	the	_	
75-10	12224-12229	study	_	
75-11	12230-12236	sample	_	
75-12	12236-12237	.	_	

#Text=There were no significant differences between the patient group and the HC group in age, gender, education, and intracranial volume (ICV) (p’s > 0.05).
76-1	12238-12243	There	_	
76-2	12244-12248	were	_	
76-3	12249-12251	no	_	
76-4	12252-12263	significant	_	
76-5	12264-12275	differences	_	
76-6	12276-12283	between	_	
76-7	12284-12287	the	_	
76-8	12288-12295	patient	_	
76-9	12296-12301	group	_	
76-10	12302-12305	and	_	
76-11	12306-12309	the	_	
76-12	12310-12312	HC	_	
76-13	12313-12318	group	_	
76-14	12319-12321	in	_	
76-15	12322-12325	age	_	
76-16	12325-12326	,	_	
76-17	12327-12333	gender	_	
76-18	12333-12334	,	_	
76-19	12335-12344	education	_	
76-20	12344-12345	,	_	
76-21	12346-12349	and	_	
76-22	12350-12362	intracranial	_	
76-23	12363-12369	volume	_	
76-24	12370-12371	(	_	
76-25	12371-12374	ICV	_	
76-26	12374-12375	)	_	
76-27	12376-12377	(	_	
76-28	12377-12378	p	_	
76-29	12378-12379	’	_	
76-30	12379-12380	s	_	
76-31	12381-12382	>	_	
76-32	12383-12387	0.05	_	
76-33	12387-12388	)	_	
76-34	12388-12389	.	_	

#Text=Demographic and clinical characteristics of the study sample.
77-1	12390-12401	Demographic	_	
77-2	12402-12405	and	_	
77-3	12406-12414	clinical	_	
77-4	12415-12430	characteristics	_	
77-5	12431-12433	of	_	
77-6	12434-12437	the	_	
77-7	12438-12443	study	_	
77-8	12444-12450	sample	_	
77-9	12450-12451	.	_	

#Text=Characteristics\tHC a (N = 25)(Mean±SD)\tSZ b (N = 37)(Mean±SD)\tt\tP\t \tAge(years)\t23.16±5.41\t22.14±5.02\t1.312\t0.195\t \tEducation(years)\t13.52±3.77\t12.81±2.12\t0.855\t0.399\t \tGender (Male/Female)\t15/10\t24/13\t\t0.791\t \tICVc (cm3)\t1623.47±141.11\t1669.23±162.50\t-1.145\t0.257\t \tAge of onset (years)\tN/A\t21.7 +3.9\t\t\t \tDuration untreated psychosis (months)\tN/A\t8.31±7.49\t\t\t \tPANSS-positive\tN/A\t21.22±2.96\t\t\t \tPANSS-negative\tN/A\t17.95±2.33\t\t\t \tPANSS-general\tN/A\t38.32±2.93\t\t\t \tPANSS-total\tN/A\t77.43±4.20\t\t\t \t
#Text=HC: healthy control group.
78-1	12452-12467	Characteristics	_	
78-2	12468-12470	HC	_	
78-3	12471-12472	a	_	
78-4	12473-12474	(	_	
78-5	12474-12475	N	_	
78-6	12476-12477	=	_	
78-7	12478-12480	25	_	
78-8	12480-12481	)	_	
78-9	12481-12482	(	_	
78-10	12482-12486	Mean	_	
78-11	12486-12487	±	_	
78-12	12487-12489	SD	_	
78-13	12489-12490	)	_	
78-14	12491-12493	SZ	_	
78-15	12494-12495	b	_	
78-16	12496-12497	(	_	
78-17	12497-12498	N	_	
78-18	12499-12500	=	_	
78-19	12501-12503	37	_	
78-20	12503-12504	)	_	
78-21	12504-12505	(	_	
78-22	12505-12509	Mean	_	
78-23	12509-12510	±	_	
78-24	12510-12512	SD	_	
78-25	12512-12513	)	_	
78-26	12514-12515	t	_	
78-27	12516-12517	P	_	
78-28	12520-12523	Age	_	
78-29	12523-12524	(	_	
78-30	12524-12529	years	_	
78-31	12529-12530	)	_	
78-32	12531-12536	23.16	_	
78-33	12536-12537	±	_	
78-34	12537-12541	5.41	_	
78-35	12542-12547	22.14	_	
78-36	12547-12548	±	_	
78-37	12548-12552	5.02	_	
78-38	12553-12558	1.312	_	
78-39	12559-12564	0.195	_	
78-40	12567-12576	Education	_	
78-41	12576-12577	(	_	
78-42	12577-12582	years	_	
78-43	12582-12583	)	_	
78-44	12584-12589	13.52	_	
78-45	12589-12590	±	_	
78-46	12590-12594	3.77	_	
78-47	12595-12600	12.81	_	
78-48	12600-12601	±	_	
78-49	12601-12605	2.12	_	
78-50	12606-12611	0.855	_	
78-51	12612-12617	0.399	_	
78-52	12620-12626	Gender	_	
78-53	12627-12628	(	_	
78-54	12628-12632	Male	_	
78-55	12632-12633	/	_	
78-56	12633-12639	Female	_	
78-57	12639-12640	)	_	
78-58	12641-12643	15	_	
78-59	12643-12644	/	_	
78-60	12644-12646	10	_	
78-61	12647-12649	24	_	
78-62	12649-12650	/	_	
78-63	12650-12652	13	_	
78-64	12654-12659	0.791	_	
78-65	12662-12666	ICVc	_	
78-66	12667-12668	(	_	
78-67	12668-12671	cm3	_	
78-68	12671-12672	)	_	
78-69	12673-12680	1623.47	_	
78-70	12680-12681	±	_	
78-71	12681-12687	141.11	_	
78-72	12688-12695	1669.23	_	
78-73	12695-12696	±	_	
78-74	12696-12702	162.50	_	
78-75	12703-12704	-	_	
78-76	12704-12709	1.145	_	
78-77	12710-12715	0.257	_	
78-78	12718-12721	Age	_	
78-79	12722-12724	of	_	
78-80	12725-12730	onset	_	
78-81	12731-12732	(	_	
78-82	12732-12737	years	_	
78-83	12737-12738	)	_	
78-84	12739-12740	N	_	
78-85	12740-12741	/	_	
78-86	12741-12742	A	_	
78-87	12743-12747	21.7	_	
78-88	12748-12749	+	_	
78-89	12749-12752	3.9	_	
78-90	12757-12765	Duration	_	
78-91	12766-12775	untreated	_	
78-92	12776-12785	psychosis	_	
78-93	12786-12787	(	_	
78-94	12787-12793	months	_	
78-95	12793-12794	)	_	
78-96	12795-12796	N	_	
78-97	12796-12797	/	_	
78-98	12797-12798	A	_	
78-99	12799-12803	8.31	_	
78-100	12803-12804	±	_	
78-101	12804-12808	7.49	_	
78-102	12813-12827	PANSS-positive	_	
78-103	12828-12829	N	_	
78-104	12829-12830	/	_	
78-105	12830-12831	A	_	
78-106	12832-12837	21.22	_	
78-107	12837-12838	±	_	
78-108	12838-12842	2.96	_	
78-109	12847-12861	PANSS-negative	_	
78-110	12862-12863	N	_	
78-111	12863-12864	/	_	
78-112	12864-12865	A	_	
78-113	12866-12871	17.95	_	
78-114	12871-12872	±	_	
78-115	12872-12876	2.33	_	
78-116	12881-12894	PANSS-general	_	
78-117	12895-12896	N	_	
78-118	12896-12897	/	_	
78-119	12897-12898	A	_	
78-120	12899-12904	38.32	_	
78-121	12904-12905	±	_	
78-122	12905-12909	2.93	_	
78-123	12914-12925	PANSS-total	_	
78-124	12926-12927	N	_	
78-125	12927-12928	/	_	
78-126	12928-12929	A	_	
78-127	12930-12935	77.43	_	
78-128	12935-12936	±	_	
78-129	12936-12940	4.20	_	
78-130	12946-12948	HC	_	
78-131	12948-12949	:	_	
78-132	12950-12957	healthy	_	
78-133	12958-12965	control	_	
78-134	12966-12971	group	_	
78-135	12971-12972	.	_	

#Text=SZ: schizophrenia patient group.
79-1	12973-12975	SZ	_	
79-2	12975-12976	:	_	
79-3	12977-12990	schizophrenia	_	
79-4	12991-12998	patient	_	
79-5	12999-13004	group	_	
79-6	13004-13005	.	_	

#Text=ICV: intracranial volume
#Text=PANSS: the Positive and Negative Syndrome Scale, including positive symptoms, negative symptoms, general psychopathology subscales and total scores.
#Text=3.1.
80-1	13006-13009	ICV	_	
80-2	13009-13010	:	_	
80-3	13011-13023	intracranial	_	
80-4	13024-13030	volume	_	
80-5	13031-13036	PANSS	_	
80-6	13036-13037	:	_	
80-7	13038-13041	the	_	
80-8	13042-13050	Positive	_	
80-9	13051-13054	and	_	
80-10	13055-13063	Negative	_	
80-11	13064-13072	Syndrome	_	
80-12	13073-13078	Scale	_	
80-13	13078-13079	,	_	
80-14	13080-13089	including	_	
80-15	13090-13098	positive	_	
80-16	13099-13107	symptoms	_	
80-17	13107-13108	,	_	
80-18	13109-13117	negative	_	
80-19	13118-13126	symptoms	_	
80-20	13126-13127	,	_	
80-21	13128-13135	general	_	
80-22	13136-13151	psychopathology	_	
80-23	13152-13161	subscales	_	
80-24	13162-13165	and	_	
80-25	13166-13171	total	_	
80-26	13172-13178	scores	_	
80-27	13178-13179	.	_	
80-28	13180-13183	3.1	_	
80-29	13183-13184	.	_	

#Text=ROI-based analysis
#Text=S1 Table shows the complete results of the seed-based analysis for each hemisphere.
81-1	13185-13194	ROI-based	_	
81-2	13195-13203	analysis	_	
81-3	13204-13206	S1	_	
81-4	13207-13212	Table	_	
81-5	13213-13218	shows	_	
81-6	13219-13222	the	_	
81-7	13223-13231	complete	_	
81-8	13232-13239	results	_	
81-9	13240-13242	of	_	
81-10	13243-13246	the	_	
81-11	13247-13257	seed-based	_	
81-12	13258-13266	analysis	_	
81-13	13267-13270	for	_	
81-14	13271-13275	each	_	
81-15	13276-13286	hemisphere	_	
81-16	13286-13287	.	_	

#Text=In the left hemisphere, no regions met the p <.001 criterion (with Bonferroni corrections) for between-group differences.
82-1	13288-13290	In	_	
82-2	13291-13294	the	_	
82-3	13295-13299	left	_	
82-4	13300-13310	hemisphere	_	
82-5	13310-13311	,	_	
82-6	13312-13314	no	_	
82-7	13315-13322	regions	_	
82-8	13323-13326	met	_	
82-9	13327-13330	the	_	
82-10	13331-13332	p	_	
82-11	13333-13334	<	_	
82-12	13334-13338	.001	_	
82-13	13339-13348	criterion	_	
82-14	13349-13350	(	_	
82-15	13350-13354	with	_	
82-16	13355-13365	Bonferroni	_	
82-17	13366-13377	corrections	_	
82-18	13377-13378	)	_	
82-19	13379-13382	for	_	
82-20	13383-13396	between-group	_	
82-21	13397-13408	differences	_	
82-22	13408-13409	.	_	

#Text=However, seven regions including caudate, Heschl’s gyrus, posterior cingulate, hippocampus, anterior and posterior parahippocampal gyrus and central operculum showed a trend-level difference (p’s <.05).
83-1	13410-13417	However	_	
83-2	13417-13418	,	_	
83-3	13419-13424	seven	_	
83-4	13425-13432	regions	_	
83-5	13433-13442	including	_	
83-6	13443-13450	caudate	_	
83-7	13450-13451	,	_	
83-8	13452-13458	Heschl	_	
83-9	13458-13459	’	_	
83-10	13459-13460	s	_	
83-11	13461-13466	gyrus	_	
83-12	13466-13467	,	_	
83-13	13468-13477	posterior	_	
83-14	13478-13487	cingulate	_	
83-15	13487-13488	,	_	
83-16	13489-13500	hippocampus	_	
83-17	13500-13501	,	_	
83-18	13502-13510	anterior	_	
83-19	13511-13514	and	_	
83-20	13515-13524	posterior	_	
83-21	13525-13540	parahippocampal	_	
83-22	13541-13546	gyrus	_	
83-23	13547-13550	and	_	
83-24	13551-13558	central	_	
83-25	13559-13568	operculum	_	
83-26	13569-13575	showed	_	
83-27	13576-13577	a	_	
83-28	13578-13589	trend-level	_	
83-29	13590-13600	difference	_	
83-30	13601-13602	(	_	
83-31	13602-13603	p	_	
83-32	13603-13604	’	_	
83-33	13604-13605	s	_	
83-34	13606-13607	<	_	
83-35	13607-13610	.05	_	
83-36	13610-13611	)	_	
83-37	13611-13612	.	_	

#Text=In the right hemisphere, three regions met the significance criterion (Heschl’s gyrus, anterior cingulate and caudate), and five regions showed a trend-level difference (central operculum, putamen, planum polare, planum temporale and thalamus).
84-1	13613-13615	In	_	
84-2	13616-13619	the	_	
84-3	13620-13625	right	_	
84-4	13626-13636	hemisphere	_	
84-5	13636-13637	,	_	
84-6	13638-13643	three	_	
84-7	13644-13651	regions	_	
84-8	13652-13655	met	_	
84-9	13656-13659	the	_	
84-10	13660-13672	significance	_	
84-11	13673-13682	criterion	_	
84-12	13683-13684	(	_	
84-13	13684-13690	Heschl	_	
84-14	13690-13691	’	_	
84-15	13691-13692	s	_	
84-16	13693-13698	gyrus	_	
84-17	13698-13699	,	_	
84-18	13700-13708	anterior	_	
84-19	13709-13718	cingulate	_	
84-20	13719-13722	and	_	
84-21	13723-13730	caudate	_	
84-22	13730-13731	)	_	
84-23	13731-13732	,	_	
84-24	13733-13736	and	_	
84-25	13737-13741	five	_	
84-26	13742-13749	regions	_	
84-27	13750-13756	showed	_	
84-28	13757-13758	a	_	
84-29	13759-13770	trend-level	_	
84-30	13771-13781	difference	_	
84-31	13782-13783	(	_	
84-32	13783-13790	central	_	
84-33	13791-13800	operculum	_	
84-34	13800-13801	,	_	
84-35	13802-13809	putamen	_	
84-36	13809-13810	,	_	
84-37	13811-13817	planum	_	
84-38	13818-13824	polare	_	
84-39	13824-13825	,	_	
84-40	13826-13832	planum	_	
84-41	13833-13842	temporale	_	
84-42	13843-13846	and	_	
84-43	13847-13855	thalamus	_	
84-44	13855-13856	)	_	
84-45	13856-13857	.	_	

#Text=Fig 1 shows the group differences in average connectivity for the regions of right insular cortical connectivity that had significant group difference.
85-1	13858-13861	Fig	_	
85-2	13862-13863	1	_	
85-3	13864-13869	shows	_	
85-4	13870-13873	the	_	
85-5	13874-13879	group	_	
85-6	13880-13891	differences	_	
85-7	13892-13894	in	_	
85-8	13895-13902	average	_	
85-9	13903-13915	connectivity	_	
85-10	13916-13919	for	_	
85-11	13920-13923	the	_	
85-12	13924-13931	regions	_	
85-13	13932-13934	of	_	
85-14	13935-13940	right	_	
85-15	13941-13948	insular	_	
85-16	13949-13957	cortical	_	
85-17	13958-13970	connectivity	_	
85-18	13971-13975	that	_	
85-19	13976-13979	had	_	
85-20	13980-13991	significant	_	
85-21	13992-13997	group	_	
85-22	13998-14008	difference	_	
85-23	14008-14009	.	_	

#Text=The regions include the right insular cortical connectivity to the right anterior cingulate cortex (ACC), right Heschl’s gyrus, and right caudate nucleus.
86-1	14010-14013	The	_	
86-2	14014-14021	regions	_	
86-3	14022-14029	include	_	
86-4	14030-14033	the	_	
86-5	14034-14039	right	_	
86-6	14040-14047	insular	_	
86-7	14048-14056	cortical	_	
86-8	14057-14069	connectivity	_	
86-9	14070-14072	to	_	
86-10	14073-14076	the	_	
86-11	14077-14082	right	_	
86-12	14083-14091	anterior	_	
86-13	14092-14101	cingulate	_	
86-14	14102-14108	cortex	_	
86-15	14109-14110	(	_	
86-16	14110-14113	ACC	_	
86-17	14113-14114	)	_	
86-18	14114-14115	,	_	
86-19	14116-14121	right	_	
86-20	14122-14128	Heschl	_	
86-21	14128-14129	’	_	
86-22	14129-14130	s	_	
86-23	14131-14136	gyrus	_	
86-24	14136-14137	,	_	
86-25	14138-14141	and	_	
86-26	14142-14147	right	_	
86-27	14148-14155	caudate	_	
86-28	14156-14163	nucleus	_	
86-29	14163-14164	.	_	

#Text=Each of these regions showed a significant decrease in the SZ group compared with the HC group.
87-1	14165-14169	Each	_	
87-2	14170-14172	of	_	
87-3	14173-14178	these	_	
87-4	14179-14186	regions	_	
87-5	14187-14193	showed	_	
87-6	14194-14195	a	_	
87-7	14196-14207	significant	_	
87-8	14208-14216	decrease	_	
87-9	14217-14219	in	_	
87-10	14220-14223	the	_	
87-11	14224-14226	SZ	_	
87-12	14227-14232	group	_	
87-13	14233-14241	compared	_	
87-14	14242-14246	with	_	
87-15	14247-14250	the	_	
87-16	14251-14253	HC	_	
87-17	14254-14259	group	_	
87-18	14259-14260	.	_	

#Text=ROI based analysis: group comparisons in the right hemisphere.
88-1	14261-14264	ROI	_	
88-2	14265-14270	based	_	
88-3	14271-14279	analysis	_	
88-4	14279-14280	:	_	
88-5	14281-14286	group	_	
88-6	14287-14298	comparisons	_	
88-7	14299-14301	in	_	
88-8	14302-14305	the	_	
88-9	14306-14311	right	_	
88-10	14312-14322	hemisphere	_	
88-11	14322-14323	.	_	

#Text=Note: Regions of right insula connectivity with significant group difference (p < 0.001, with Bonferroni corrections): right anterior cingulate, right Heschl’s gyrus and right caudate.
89-1	14324-14328	Note	_	
89-2	14328-14329	:	_	
89-3	14330-14337	Regions	_	
89-4	14338-14340	of	_	
89-5	14341-14346	right	_	
89-6	14347-14353	insula	_	
89-7	14354-14366	connectivity	_	
89-8	14367-14371	with	_	
89-9	14372-14383	significant	_	
89-10	14384-14389	group	_	
89-11	14390-14400	difference	_	
89-12	14401-14402	(	_	
89-13	14402-14403	p	_	
89-14	14404-14405	<	_	
89-15	14406-14411	0.001	_	
89-16	14411-14412	,	_	
89-17	14413-14417	with	_	
89-18	14418-14428	Bonferroni	_	
89-19	14429-14440	corrections	_	
89-20	14440-14441	)	_	
89-21	14441-14442	:	_	
89-22	14443-14448	right	_	
89-23	14449-14457	anterior	_	
89-24	14458-14467	cingulate	_	
89-25	14467-14468	,	_	
89-26	14469-14474	right	_	
89-27	14475-14481	Heschl	_	
89-28	14481-14482	’	_	
89-29	14482-14483	s	_	
89-30	14484-14489	gyrus	_	
89-31	14490-14493	and	_	
89-32	14494-14499	right	_	
89-33	14500-14507	caudate	_	
89-34	14507-14508	.	_	

#Text=The horizontal lines represent means and the error bars represent 95% confidence intervals.
#Text=3.2.
90-1	14509-14512	The	_	
90-2	14513-14523	horizontal	_	
90-3	14524-14529	lines	_	
90-4	14530-14539	represent	_	
90-5	14540-14545	means	_	
90-6	14546-14549	and	_	
90-7	14550-14553	the	_	
90-8	14554-14559	error	_	
90-9	14560-14564	bars	_	
90-10	14565-14574	represent	_	
90-11	14575-14578	95%	_	
90-12	14579-14589	confidence	_	
90-13	14590-14599	intervals	_	
90-14	14599-14600	.	_	
90-15	14601-14604	3.2	_	
90-16	14604-14605	.	_	

#Text=Confirmatory voxel-based analysis
#Text=Fig 2 shows the results of the VBM analysis for the right hemisphere insula-seeded correlation maps.
91-1	14606-14618	Confirmatory	_	
91-2	14619-14630	voxel-based	_	
91-3	14631-14639	analysis	_	
91-4	14640-14643	Fig	_	
91-5	14644-14645	2	_	
91-6	14646-14651	shows	_	
91-7	14652-14655	the	_	
91-8	14656-14663	results	_	
91-9	14664-14666	of	_	
91-10	14667-14670	the	_	
91-11	14671-14674	VBM	_	
91-12	14675-14683	analysis	_	
91-13	14684-14687	for	_	
91-14	14688-14691	the	_	
91-15	14692-14697	right	_	
91-16	14698-14708	hemisphere	_	
91-17	14709-14722	insula-seeded	_	
91-18	14723-14734	correlation	_	
91-19	14735-14739	maps	_	
91-20	14739-14740	.	_	

#Text=A FDR—corrected significant cluster was observed in Heschl’s gyrus.
92-1	14741-14742	A	_	
92-2	14743-14756	FDR—corrected	_	
92-3	14757-14768	significant	_	
92-4	14769-14776	cluster	_	
92-5	14777-14780	was	_	
92-6	14781-14789	observed	_	
92-7	14790-14792	in	_	
92-8	14793-14799	Heschl	_	
92-9	14799-14800	’	_	
92-10	14800-14801	s	_	
92-11	14802-14807	gyrus	_	
92-12	14807-14808	.	_	

#Text=An additional significant cluster was observed in the superior temporal gyrus.
93-1	14809-14811	An	_	
93-2	14812-14822	additional	_	
93-3	14823-14834	significant	_	
93-4	14835-14842	cluster	_	
93-5	14843-14846	was	_	
93-6	14847-14855	observed	_	
93-7	14856-14858	in	_	
93-8	14859-14862	the	_	
93-9	14863-14871	superior	_	
93-10	14872-14880	temporal	_	
93-11	14881-14886	gyrus	_	
93-12	14886-14887	.	_	

#Text=FDR trend-level clusters were also observed in the anterior cingulate gyrus and caudate nucleus.
94-1	14888-14891	FDR	_	
94-2	14892-14903	trend-level	_	
94-3	14904-14912	clusters	_	
94-4	14913-14917	were	_	
94-5	14918-14922	also	_	
94-6	14923-14931	observed	_	
94-7	14932-14934	in	_	
94-8	14935-14938	the	_	
94-9	14939-14947	anterior	_	
94-10	14948-14957	cingulate	_	
94-11	14958-14963	gyrus	_	
94-12	14964-14967	and	_	
94-13	14968-14975	caudate	_	
94-14	14976-14983	nucleus	_	
94-15	14983-14984	.	_	

#Text=Thus, of the three ROI-based regions in the right hemisphere with significant betwee-group difference, only the Heschl’s gyrus difference was confirmed in the VBM analysis.
95-1	14985-14989	Thus	_	
95-2	14989-14990	,	_	
95-3	14991-14993	of	_	
95-4	14994-14997	the	_	
95-5	14998-15003	three	_	
95-6	15004-15013	ROI-based	_	
95-7	15014-15021	regions	_	
95-8	15022-15024	in	_	
95-9	15025-15028	the	_	
95-10	15029-15034	right	_	
95-11	15035-15045	hemisphere	_	
95-12	15046-15050	with	_	
95-13	15051-15062	significant	_	
95-14	15063-15075	betwee-group	_	
95-15	15076-15086	difference	_	
95-16	15086-15087	,	_	
95-17	15088-15092	only	_	
95-18	15093-15096	the	_	
95-19	15097-15103	Heschl	_	
95-20	15103-15104	’	_	
95-21	15104-15105	s	_	
95-22	15106-15111	gyrus	_	
95-23	15112-15122	difference	_	
95-24	15123-15126	was	_	
95-25	15127-15136	confirmed	_	
95-26	15137-15139	in	_	
95-27	15140-15143	the	_	
95-28	15144-15147	VBM	_	
95-29	15148-15156	analysis	_	
95-30	15156-15157	.	_	

#Text=Voxel-based analysis for the right hemisphere insula-seeded correlation maps.
96-1	15158-15169	Voxel-based	_	
96-2	15170-15178	analysis	_	
96-3	15179-15182	for	_	
96-4	15183-15186	the	_	
96-5	15187-15192	right	_	
96-6	15193-15203	hemisphere	_	
96-7	15204-15217	insula-seeded	_	
96-8	15218-15229	correlation	_	
96-9	15230-15234	maps	_	
96-10	15234-15235	.	_	

#Text=Note: FDR-corrected significant clusters: Heschl’s gyrus, superior temporal gyrus (p’s < 0.05); FDR trend-level clusters: anterior cingulate gyrus, caudate.
#Text=3.3.
97-1	15236-15240	Note	_	
97-2	15240-15241	:	_	
97-3	15242-15255	FDR-corrected	_	
97-4	15256-15267	significant	_	
97-5	15268-15276	clusters	_	
97-6	15276-15277	:	_	
97-7	15278-15284	Heschl	_	
97-8	15284-15285	’	_	
97-9	15285-15286	s	_	
97-10	15287-15292	gyrus	_	
97-11	15292-15293	,	_	
97-12	15294-15302	superior	_	
97-13	15303-15311	temporal	_	
97-14	15312-15317	gyrus	_	
97-15	15318-15319	(	_	
97-16	15319-15320	p	_	
97-17	15320-15321	’	_	
97-18	15321-15322	s	_	
97-19	15323-15324	<	_	
97-20	15325-15329	0.05	_	
97-21	15329-15330	)	_	
97-22	15330-15331	;	_	
97-23	15332-15335	FDR	_	
97-24	15336-15347	trend-level	_	
97-25	15348-15356	clusters	_	
97-26	15356-15357	:	_	
97-27	15358-15366	anterior	_	
97-28	15367-15376	cingulate	_	
97-29	15377-15382	gyrus	_	
97-30	15382-15383	,	_	
97-31	15384-15391	caudate	_	
97-32	15391-15392	.	_	
97-33	15393-15396	3.3	_	
97-34	15396-15397	.	_	

#Text=Correlation with clinical symptoms
#Text=The relationship between the resting state average Z-scores of insula-Heschl’s gyrus connectivity and the measures of clinical symptoms were examined in both hemispheres.
98-1	15398-15409	Correlation	_	
98-2	15410-15414	with	_	
98-3	15415-15423	clinical	_	
98-4	15424-15432	symptoms	_	
98-5	15433-15436	The	_	
98-6	15437-15449	relationship	_	
98-7	15450-15457	between	_	
98-8	15458-15461	the	_	
98-9	15462-15469	resting	_	
98-10	15470-15475	state	_	
98-11	15476-15483	average	_	
98-12	15484-15492	Z-scores	_	
98-13	15493-15495	of	_	
98-14	15496-15509	insula-Heschl	_	
98-15	15509-15510	’	_	
98-16	15510-15511	s	_	
98-17	15512-15517	gyrus	_	
98-18	15518-15530	connectivity	_	
98-19	15531-15534	and	_	
98-20	15535-15538	the	_	
98-21	15539-15547	measures	_	
98-22	15548-15550	of	_	
98-23	15551-15559	clinical	_	
98-24	15560-15568	symptoms	_	
98-25	15569-15573	were	_	
98-26	15574-15582	examined	_	
98-27	15583-15585	in	_	
98-28	15586-15590	both	_	
98-29	15591-15602	hemispheres	_	
98-30	15602-15603	.	_	

#Text=As shown in Fig 3, there was a significant negative correlation between the left insula-Heschl’s gyrus connectivity and the PANSS negative symptoms subscale scores (r = -0.406, p = 0.019), and a significant positive correlation between the right insula—Heschl’s gyrus and the PANSS general psychopathology subscale scores (r = 0.384, p = 0.019).
99-1	15604-15606	As	_	
99-2	15607-15612	shown	_	
99-3	15613-15615	in	_	
99-4	15616-15619	Fig	_	
99-5	15620-15621	3	_	
99-6	15621-15622	,	_	
99-7	15623-15628	there	_	
99-8	15629-15632	was	_	
99-9	15633-15634	a	_	
99-10	15635-15646	significant	_	
99-11	15647-15655	negative	_	
99-12	15656-15667	correlation	_	
99-13	15668-15675	between	_	
99-14	15676-15679	the	_	
99-15	15680-15684	left	_	
99-16	15685-15698	insula-Heschl	_	
99-17	15698-15699	’	_	
99-18	15699-15700	s	_	
99-19	15701-15706	gyrus	_	
99-20	15707-15719	connectivity	_	
99-21	15720-15723	and	_	
99-22	15724-15727	the	_	
99-23	15728-15733	PANSS	_	
99-24	15734-15742	negative	_	
99-25	15743-15751	symptoms	_	
99-26	15752-15760	subscale	_	
99-27	15761-15767	scores	_	
99-28	15768-15769	(	_	
99-29	15769-15770	r	_	
99-30	15771-15772	=	_	
99-31	15773-15774	-	_	
99-32	15774-15779	0.406	_	
99-33	15779-15780	,	_	
99-34	15781-15782	p	_	
99-35	15783-15784	=	_	
99-36	15785-15790	0.019	_	
99-37	15790-15791	)	_	
99-38	15791-15792	,	_	
99-39	15793-15796	and	_	
99-40	15797-15798	a	_	
99-41	15799-15810	significant	_	
99-42	15811-15819	positive	_	
99-43	15820-15831	correlation	_	
99-44	15832-15839	between	_	
99-45	15840-15843	the	_	
99-46	15844-15849	right	_	
99-47	15850-15863	insula—Heschl	_	
99-48	15863-15864	’	_	
99-49	15864-15865	s	_	
99-50	15866-15871	gyrus	_	
99-51	15872-15875	and	_	
99-52	15876-15879	the	_	
99-53	15880-15885	PANSS	_	
99-54	15886-15893	general	_	
99-55	15894-15909	psychopathology	_	
99-56	15910-15918	subscale	_	
99-57	15919-15925	scores	_	
99-58	15926-15927	(	_	
99-59	15927-15928	r	_	
99-60	15929-15930	=	_	
99-61	15931-15936	0.384	_	
99-62	15936-15937	,	_	
99-63	15938-15939	p	_	
99-64	15940-15941	=	_	
99-65	15942-15947	0.019	_	
99-66	15947-15948	)	_	
99-67	15948-15949	.	_	

#Text=Relationship between insula functional connectivity and clinical symptoms.
#Text=4.
100-1	15950-15962	Relationship	_	
100-2	15963-15970	between	_	
100-3	15971-15977	insula	_	
100-4	15978-15988	functional	_	
100-5	15989-16001	connectivity	_	
100-6	16002-16005	and	_	
100-7	16006-16014	clinical	_	
100-8	16015-16023	symptoms	_	
100-9	16023-16024	.	_	
100-10	16025-16026	4	_	
100-11	16026-16027	.	_	

#Text=Discussion
#Text=Minimizing the potential confounding effect of antipsychotics, the present study provides new evidence regarding changes in insula-Heschl gyrus connectivity in drug naïve, first episode schizophrenia patients.
101-1	16028-16038	Discussion	_	
101-2	16039-16049	Minimizing	_	
101-3	16050-16053	the	_	
101-4	16054-16063	potential	_	
101-5	16064-16075	confounding	_	
101-6	16076-16082	effect	_	
101-7	16083-16085	of	_	
101-8	16086-16100	antipsychotics	_	
101-9	16100-16101	,	_	
101-10	16102-16105	the	_	
101-11	16106-16113	present	_	
101-12	16114-16119	study	_	
101-13	16120-16128	provides	_	
101-14	16129-16132	new	_	
101-15	16133-16141	evidence	_	
101-16	16142-16151	regarding	_	
101-17	16152-16159	changes	_	
101-18	16160-16162	in	_	
101-19	16163-16176	insula-Heschl	_	
101-20	16177-16182	gyrus	_	
101-21	16183-16195	connectivity	_	
101-22	16196-16198	in	_	
101-23	16199-16203	drug	_	
101-24	16204-16209	naïve	_	
101-25	16209-16210	,	_	
101-26	16211-16216	first	_	
101-27	16217-16224	episode	_	
101-28	16225-16238	schizophrenia	_	
101-29	16239-16247	patients	_	
101-30	16247-16248	.	_	

#Text=In this study, we found that there was significant reduction in the insular cortical connectivity with Heschl’s gyrus, anterior cingulate cortex (ACC), and caudate nucleus in the right hemisphere.
102-1	16249-16251	In	_	
102-2	16252-16256	this	_	
102-3	16257-16262	study	_	
102-4	16262-16263	,	_	
102-5	16264-16266	we	_	
102-6	16267-16272	found	_	
102-7	16273-16277	that	_	
102-8	16278-16283	there	_	
102-9	16284-16287	was	_	
102-10	16288-16299	significant	_	
102-11	16300-16309	reduction	_	
102-12	16310-16312	in	_	
102-13	16313-16316	the	_	
102-14	16317-16324	insular	_	
102-15	16325-16333	cortical	_	
102-16	16334-16346	connectivity	_	
102-17	16347-16351	with	_	
102-18	16352-16358	Heschl	_	
102-19	16358-16359	’	_	
102-20	16359-16360	s	_	
102-21	16361-16366	gyrus	_	
102-22	16366-16367	,	_	
102-23	16368-16376	anterior	_	
102-24	16377-16386	cingulate	_	
102-25	16387-16393	cortex	_	
102-26	16394-16395	(	_	
102-27	16395-16398	ACC	_	
102-28	16398-16399	)	_	
102-29	16399-16400	,	_	
102-30	16401-16404	and	_	
102-31	16405-16412	caudate	_	
102-32	16413-16420	nucleus	_	
102-33	16421-16423	in	_	
102-34	16424-16427	the	_	
102-35	16428-16433	right	_	
102-36	16434-16444	hemisphere	_	
102-37	16444-16445	.	_	

#Text=We also found that the insula-Heschis connectivity might be associated withclinical symptoms of schizophrenia.
103-1	16446-16448	We	_	
103-2	16449-16453	also	_	
103-3	16454-16459	found	_	
103-4	16460-16464	that	_	
103-5	16465-16468	the	_	
103-6	16469-16483	insula-Heschis	_	
103-7	16484-16496	connectivity	_	
103-8	16497-16502	might	_	
103-9	16503-16505	be	_	
103-10	16506-16516	associated	_	
103-11	16517-16529	withclinical	_	
103-12	16530-16538	symptoms	_	
103-13	16539-16541	of	_	
103-14	16542-16555	schizophrenia	_	
103-15	16555-16556	.	_	

#Text=Reduced insular cortical connectivity with Heschl’s gyrus in the right brain hemisphere was found in the seed-based analysis and was confirmed in the VBM analysis.
104-1	16557-16564	Reduced	_	
104-2	16565-16572	insular	_	
104-3	16573-16581	cortical	_	
104-4	16582-16594	connectivity	_	
104-5	16595-16599	with	_	
104-6	16600-16606	Heschl	_	
104-7	16606-16607	’	_	
104-8	16607-16608	s	_	
104-9	16609-16614	gyrus	_	
104-10	16615-16617	in	_	
104-11	16618-16621	the	_	
104-12	16622-16627	right	_	
104-13	16628-16633	brain	_	
104-14	16634-16644	hemisphere	_	
104-15	16645-16648	was	_	
104-16	16649-16654	found	_	
104-17	16655-16657	in	_	
104-18	16658-16661	the	_	
104-19	16662-16672	seed-based	_	
104-20	16673-16681	analysis	_	
104-21	16682-16685	and	_	
104-22	16686-16689	was	_	
104-23	16690-16699	confirmed	_	
104-24	16700-16702	in	_	
104-25	16703-16706	the	_	
104-26	16707-16710	VBM	_	
104-27	16711-16719	analysis	_	
104-28	16719-16720	.	_	

#Text=Similar to insular cortex, Heschl's gyrus (transverse temporal gyrus) may also play an important role in the neural mechanism of schizophrenia.
105-1	16721-16728	Similar	_	
105-2	16729-16731	to	_	
105-3	16732-16739	insular	_	
105-4	16740-16746	cortex	_	
105-5	16746-16747	,	_	
105-6	16748-16756	Heschl's	_	
105-7	16757-16762	gyrus	_	
105-8	16763-16764	(	_	
105-9	16764-16774	transverse	_	
105-10	16775-16783	temporal	_	
105-11	16784-16789	gyrus	_	
105-12	16789-16790	)	_	
105-13	16791-16794	may	_	
105-14	16795-16799	also	_	
105-15	16800-16804	play	_	
105-16	16805-16807	an	_	
105-17	16808-16817	important	_	
105-18	16818-16822	role	_	
105-19	16823-16825	in	_	
105-20	16826-16829	the	_	
105-21	16830-16836	neural	_	
105-22	16837-16846	mechanism	_	
105-23	16847-16849	of	_	
105-24	16850-16863	schizophrenia	_	
105-25	16863-16864	.	_	

#Text=It has been reported that first-episode schizophrenia patients have bilateral Heschl’s gyrus gray matter volume reduction, and decreased left Heschl’s gyrus gray matter volume over time.
106-1	16865-16867	It	_	
106-2	16868-16871	has	_	
106-3	16872-16876	been	_	
106-4	16877-16885	reported	_	
106-5	16886-16890	that	_	
106-6	16891-16904	first-episode	_	
106-7	16905-16918	schizophrenia	_	
106-8	16919-16927	patients	_	
106-9	16928-16932	have	_	
106-10	16933-16942	bilateral	_	
106-11	16943-16949	Heschl	_	
106-12	16949-16950	’	_	
106-13	16950-16951	s	_	
106-14	16952-16957	gyrus	_	
106-15	16958-16962	gray	_	
106-16	16963-16969	matter	_	
106-17	16970-16976	volume	_	
106-18	16977-16986	reduction	_	
106-19	16986-16987	,	_	
106-20	16988-16991	and	_	
106-21	16992-17001	decreased	_	
106-22	17002-17006	left	_	
106-23	17007-17013	Heschl	_	
106-24	17013-17014	’	_	
106-25	17014-17015	s	_	
106-26	17016-17021	gyrus	_	
106-27	17022-17026	gray	_	
106-28	17027-17033	matter	_	
106-29	17034-17040	volume	_	
106-30	17041-17045	over	_	
106-31	17046-17050	time	_	
106-32	17050-17051	.	_	

#Text=Heschl's gyrus contains the primary auditory cortex (PAC), which is the first cortical structure to process incoming auditory information.
107-1	17052-17060	Heschl's	_	
107-2	17061-17066	gyrus	_	
107-3	17067-17075	contains	_	
107-4	17076-17079	the	_	
107-5	17080-17087	primary	_	
107-6	17088-17096	auditory	_	
107-7	17097-17103	cortex	_	
107-8	17104-17105	(	_	
107-9	17105-17108	PAC	_	
107-10	17108-17109	)	_	
107-11	17109-17110	,	_	
107-12	17111-17116	which	_	
107-13	17117-17119	is	_	
107-14	17120-17123	the	_	
107-15	17124-17129	first	_	
107-16	17130-17138	cortical	_	
107-17	17139-17148	structure	_	
107-18	17149-17151	to	_	
107-19	17152-17159	process	_	
107-20	17160-17168	incoming	_	
107-21	17169-17177	auditory	_	
107-22	17178-17189	information	_	
107-23	17189-17190	.	_	

#Text=The PAC is in close spatial proximity to the posteroinferior insular cortex.
108-1	17191-17194	The	_	
108-2	17195-17198	PAC	_	
108-3	17199-17201	is	_	
108-4	17202-17204	in	_	
108-5	17205-17210	close	_	
108-6	17211-17218	spatial	_	
108-7	17219-17228	proximity	_	
108-8	17229-17231	to	_	
108-9	17232-17235	the	_	
108-10	17236-17251	posteroinferior	_	
108-11	17252-17259	insular	_	
108-12	17260-17266	cortex	_	
108-13	17266-17267	.	_	

#Text=The auditory information related to prosodic processing may be conveyed to the posterior insular cortex directly through links with the primary auditory and association areas.
109-1	17268-17271	The	_	
109-2	17272-17280	auditory	_	
109-3	17281-17292	information	_	
109-4	17293-17300	related	_	
109-5	17301-17303	to	_	
109-6	17304-17312	prosodic	_	
109-7	17313-17323	processing	_	
109-8	17324-17327	may	_	
109-9	17328-17330	be	_	
109-10	17331-17339	conveyed	_	
109-11	17340-17342	to	_	
109-12	17343-17346	the	_	
109-13	17347-17356	posterior	_	
109-14	17357-17364	insular	_	
109-15	17365-17371	cortex	_	
109-16	17372-17380	directly	_	
109-17	17381-17388	through	_	
109-18	17389-17394	links	_	
109-19	17395-17399	with	_	
109-20	17400-17403	the	_	
109-21	17404-17411	primary	_	
109-22	17412-17420	auditory	_	
109-23	17421-17424	and	_	
109-24	17425-17436	association	_	
109-25	17437-17442	areas	_	
109-26	17442-17443	.	_	

#Text=These findings suggest that deficits in the right insula-Heschl’s functional connectivity may be engaged in the prosody dysfunction in patients with schizophrenia.
110-1	17444-17449	These	_	
110-2	17450-17458	findings	_	
110-3	17459-17466	suggest	_	
110-4	17467-17471	that	_	
110-5	17472-17480	deficits	_	
110-6	17481-17483	in	_	
110-7	17484-17487	the	_	
110-8	17488-17493	right	_	
110-9	17494-17507	insula-Heschl	_	
110-10	17507-17508	’	_	
110-11	17508-17509	s	_	
110-12	17510-17520	functional	_	
110-13	17521-17533	connectivity	_	
110-14	17534-17537	may	_	
110-15	17538-17540	be	_	
110-16	17541-17548	engaged	_	
110-17	17549-17551	in	_	
110-18	17552-17555	the	_	
110-19	17556-17563	prosody	_	
110-20	17564-17575	dysfunction	_	
110-21	17576-17578	in	_	
110-22	17579-17587	patients	_	
110-23	17588-17592	with	_	
110-24	17593-17606	schizophrenia	_	
110-25	17606-17607	.	_	

#Text=Reduced right insula-caudate connectivity is another finding in the present study based on the seed-based analysis.
111-1	17608-17615	Reduced	_	
111-2	17616-17621	right	_	
111-3	17622-17636	insula-caudate	_	
111-4	17637-17649	connectivity	_	
111-5	17650-17652	is	_	
111-6	17653-17660	another	_	
111-7	17661-17668	finding	_	
111-8	17669-17671	in	_	
111-9	17672-17675	the	_	
111-10	17676-17683	present	_	
111-11	17684-17689	study	_	
111-12	17690-17695	based	_	
111-13	17696-17698	on	_	
111-14	17699-17702	the	_	
111-15	17703-17713	seed-based	_	
111-16	17714-17722	analysis	_	
111-17	17722-17723	.	_	

#Text=Caudate nucleus is related to successful goal-directed action.
112-1	17724-17731	Caudate	_	
112-2	17732-17739	nucleus	_	
112-3	17740-17742	is	_	
112-4	17743-17750	related	_	
112-5	17751-17753	to	_	
112-6	17754-17764	successful	_	
112-7	17765-17778	goal-directed	_	
112-8	17779-17785	action	_	
112-9	17785-17786	.	_	

#Text=Studies have found that schizophrenia and their relatives have a reduced caudate volume and compromised white matter integrity.
113-1	17787-17794	Studies	_	
113-2	17795-17799	have	_	
113-3	17800-17805	found	_	
113-4	17806-17810	that	_	
113-5	17811-17824	schizophrenia	_	
113-6	17825-17828	and	_	
113-7	17829-17834	their	_	
113-8	17835-17844	relatives	_	
113-9	17845-17849	have	_	
113-10	17850-17851	a	_	
113-11	17852-17859	reduced	_	
113-12	17860-17867	caudate	_	
113-13	17868-17874	volume	_	
113-14	17875-17878	and	_	
113-15	17879-17890	compromised	_	
113-16	17891-17896	white	_	
113-17	17897-17903	matter	_	
113-18	17904-17913	integrity	_	
113-19	17913-17914	.	_	

#Text=Using functional magnetic resonance imaging to study brain activation during a Monetary Incentive Delay task, Mucci et al. found that avolition in patients with schizophrenia might be related to dorsal caudate hypo-activation.
114-1	17915-17920	Using	_	
114-2	17921-17931	functional	_	
114-3	17932-17940	magnetic	_	
114-4	17941-17950	resonance	_	
114-5	17951-17958	imaging	_	
114-6	17959-17961	to	_	
114-7	17962-17967	study	_	
114-8	17968-17973	brain	_	
114-9	17974-17984	activation	_	
114-10	17985-17991	during	_	
114-11	17992-17993	a	_	
114-12	17994-18002	Monetary	_	
114-13	18003-18012	Incentive	_	
114-14	18013-18018	Delay	_	
114-15	18019-18023	task	_	
114-16	18023-18024	,	_	
114-17	18025-18030	Mucci	_	
114-18	18031-18033	et	_	
114-19	18034-18036	al	_	
114-20	18036-18037	.	_	
114-21	18038-18043	found	_	
114-22	18044-18048	that	_	
114-23	18049-18058	avolition	_	
114-24	18059-18061	in	_	
114-25	18062-18070	patients	_	
114-26	18071-18075	with	_	
114-27	18076-18089	schizophrenia	_	
114-28	18090-18095	might	_	
114-29	18096-18098	be	_	
114-30	18099-18106	related	_	
114-31	18107-18109	to	_	
114-32	18110-18116	dorsal	_	
114-33	18117-18124	caudate	_	
114-34	18125-18140	hypo-activation	_	
114-35	18140-18141	.	_	

#Text=Another research team has reported an abnormal hemispheric specialization of caudate nucleus connectivity in schizophrenia.
115-1	18142-18149	Another	_	
115-2	18150-18158	research	_	
115-3	18159-18163	team	_	
115-4	18164-18167	has	_	
115-5	18168-18176	reported	_	
115-6	18177-18179	an	_	
115-7	18180-18188	abnormal	_	
115-8	18189-18200	hemispheric	_	
115-9	18201-18215	specialization	_	
115-10	18216-18218	of	_	
115-11	18219-18226	caudate	_	
115-12	18227-18234	nucleus	_	
115-13	18235-18247	connectivity	_	
115-14	18248-18250	in	_	
115-15	18251-18264	schizophrenia	_	
115-16	18264-18265	.	_	

#Text=Reduced insula-caudate connectivity found in our study may play an important role in the development of schizophrenia.
116-1	18266-18273	Reduced	_	
116-2	18274-18288	insula-caudate	_	
116-3	18289-18301	connectivity	_	
116-4	18302-18307	found	_	
116-5	18308-18310	in	_	
116-6	18311-18314	our	_	
116-7	18315-18320	study	_	
116-8	18321-18324	may	_	
116-9	18325-18329	play	_	
116-10	18330-18332	an	_	
116-11	18333-18342	important	_	
116-12	18343-18347	role	_	
116-13	18348-18350	in	_	
116-14	18351-18354	the	_	
116-15	18355-18366	development	_	
116-16	18367-18369	of	_	
116-17	18370-18383	schizophrenia	_	
116-18	18383-18384	.	_	

#Text=We also found significantly decreased right insula connectivity with ACC using the ROI-based analysis.
117-1	18385-18387	We	_	
117-2	18388-18392	also	_	
117-3	18393-18398	found	_	
117-4	18399-18412	significantly	_	
117-5	18413-18422	decreased	_	
117-6	18423-18428	right	_	
117-7	18429-18435	insula	_	
117-8	18436-18448	connectivity	_	
117-9	18449-18453	with	_	
117-10	18454-18457	ACC	_	
117-11	18458-18463	using	_	
117-12	18464-18467	the	_	
117-13	18468-18477	ROI-based	_	
117-14	18478-18486	analysis	_	
117-15	18486-18487	.	_	

#Text=The insula and ACC together constitute the SN, an intrinsic large-scale network showing strong functional connectivity.
118-1	18488-18491	The	_	
118-2	18492-18498	insula	_	
118-3	18499-18502	and	_	
118-4	18503-18506	ACC	_	
118-5	18507-18515	together	_	
118-6	18516-18526	constitute	_	
118-7	18527-18530	the	_	
118-8	18531-18533	SN	_	
118-9	18533-18534	,	_	
118-10	18535-18537	an	_	
118-11	18538-18547	intrinsic	_	
118-12	18548-18559	large-scale	_	
118-13	18560-18567	network	_	
118-14	18568-18575	showing	_	
118-15	18576-18582	strong	_	
118-16	18583-18593	functional	_	
118-17	18594-18606	connectivity	_	
118-18	18606-18607	.	_	

#Text=Menon and Uddin have recently proposed that the primary role of this network is to segregate the most relevant stimuli among internal and extra-personal stimuli, to assist target brain regions and generate appropriate behavioral responses to salient stimuli, and to enable switching between the default mode and task-related states of brain connectivity.
119-1	18608-18613	Menon	_	
119-2	18614-18617	and	_	
119-3	18618-18623	Uddin	_	
119-4	18624-18628	have	_	
119-5	18629-18637	recently	_	
119-6	18638-18646	proposed	_	
119-7	18647-18651	that	_	
119-8	18652-18655	the	_	
119-9	18656-18663	primary	_	
119-10	18664-18668	role	_	
119-11	18669-18671	of	_	
119-12	18672-18676	this	_	
119-13	18677-18684	network	_	
119-14	18685-18687	is	_	
119-15	18688-18690	to	_	
119-16	18691-18700	segregate	_	
119-17	18701-18704	the	_	
119-18	18705-18709	most	_	
119-19	18710-18718	relevant	_	
119-20	18719-18726	stimuli	_	
119-21	18727-18732	among	_	
119-22	18733-18741	internal	_	
119-23	18742-18745	and	_	
119-24	18746-18760	extra-personal	_	
119-25	18761-18768	stimuli	_	
119-26	18768-18769	,	_	
119-27	18770-18772	to	_	
119-28	18773-18779	assist	_	
119-29	18780-18786	target	_	
119-30	18787-18792	brain	_	
119-31	18793-18800	regions	_	
119-32	18801-18804	and	_	
119-33	18805-18813	generate	_	
119-34	18814-18825	appropriate	_	
119-35	18826-18836	behavioral	_	
119-36	18837-18846	responses	_	
119-37	18847-18849	to	_	
119-38	18850-18857	salient	_	
119-39	18858-18865	stimuli	_	
119-40	18865-18866	,	_	
119-41	18867-18870	and	_	
119-42	18871-18873	to	_	
119-43	18874-18880	enable	_	
119-44	18881-18890	switching	_	
119-45	18891-18898	between	_	
119-46	18899-18902	the	_	
119-47	18903-18910	default	_	
119-48	18911-18915	mode	_	
119-49	18916-18919	and	_	
119-50	18920-18932	task-related	_	
119-51	18933-18939	states	_	
119-52	18940-18942	of	_	
119-53	18943-18948	brain	_	
119-54	18949-18961	connectivity	_	
119-55	18961-18962	.	_	

#Text=Abnormal connectivity of SN has been reported to be associated with the negative symptoms, hallucinations, delusions and other psychotic symptoms of schizophrenia.
120-1	18963-18971	Abnormal	_	
120-2	18972-18984	connectivity	_	
120-3	18985-18987	of	_	
120-4	18988-18990	SN	_	
120-5	18991-18994	has	_	
120-6	18995-18999	been	_	
120-7	19000-19008	reported	_	
120-8	19009-19011	to	_	
120-9	19012-19014	be	_	
120-10	19015-19025	associated	_	
120-11	19026-19030	with	_	
120-12	19031-19034	the	_	
120-13	19035-19043	negative	_	
120-14	19044-19052	symptoms	_	
120-15	19052-19053	,	_	
120-16	19054-19068	hallucinations	_	
120-17	19068-19069	,	_	
120-18	19070-19079	delusions	_	
120-19	19080-19083	and	_	
120-20	19084-19089	other	_	
120-21	19090-19099	psychotic	_	
120-22	19100-19108	symptoms	_	
120-23	19109-19111	of	_	
120-24	19112-19125	schizophrenia	_	
120-25	19125-19126	.	_	

#Text=Previous studies have suggested that functional and/or structural alterations within the insular cortex might contribute to aberrant salience processing, leading to the development of schizophrenia symptoms.
121-1	19127-19135	Previous	_	
121-2	19136-19143	studies	_	
121-3	19144-19148	have	_	
121-4	19149-19158	suggested	_	
121-5	19159-19163	that	_	
121-6	19164-19174	functional	_	
121-7	19175-19178	and	_	
121-8	19178-19179	/	_	
121-9	19179-19181	or	_	
121-10	19182-19192	structural	_	
121-11	19193-19204	alterations	_	
121-12	19205-19211	within	_	
121-13	19212-19215	the	_	
121-14	19216-19223	insular	_	
121-15	19224-19230	cortex	_	
121-16	19231-19236	might	_	
121-17	19237-19247	contribute	_	
121-18	19248-19250	to	_	
121-19	19251-19259	aberrant	_	
121-20	19260-19268	salience	_	
121-21	19269-19279	processing	_	
121-22	19279-19280	,	_	
121-23	19281-19288	leading	_	
121-24	19289-19291	to	_	
121-25	19292-19295	the	_	
121-26	19296-19307	development	_	
121-27	19308-19310	of	_	
121-28	19311-19324	schizophrenia	_	
121-29	19325-19333	symptoms	_	
121-30	19333-19334	.	_	

#Text=In the present study, our correlation analysis within the patient group showed a significant negative relationship between left insula-Heschl’s gyrus connectivity and the PANSS negative symptoms subscale scores, suggesting the impairment in this particular functional connectivity might be related to the development of negative symptoms of schizophrenia.
122-1	19335-19337	In	_	
122-2	19338-19341	the	_	
122-3	19342-19349	present	_	
122-4	19350-19355	study	_	
122-5	19355-19356	,	_	
122-6	19357-19360	our	_	
122-7	19361-19372	correlation	_	
122-8	19373-19381	analysis	_	
122-9	19382-19388	within	_	
122-10	19389-19392	the	_	
122-11	19393-19400	patient	_	
122-12	19401-19406	group	_	
122-13	19407-19413	showed	_	
122-14	19414-19415	a	_	
122-15	19416-19427	significant	_	
122-16	19428-19436	negative	_	
122-17	19437-19449	relationship	_	
122-18	19450-19457	between	_	
122-19	19458-19462	left	_	
122-20	19463-19476	insula-Heschl	_	
122-21	19476-19477	’	_	
122-22	19477-19478	s	_	
122-23	19479-19484	gyrus	_	
122-24	19485-19497	connectivity	_	
122-25	19498-19501	and	_	
122-26	19502-19505	the	_	
122-27	19506-19511	PANSS	_	
122-28	19512-19520	negative	_	
122-29	19521-19529	symptoms	_	
122-30	19530-19538	subscale	_	
122-31	19539-19545	scores	_	
122-32	19545-19546	,	_	
122-33	19547-19557	suggesting	_	
122-34	19558-19561	the	_	
122-35	19562-19572	impairment	_	
122-36	19573-19575	in	_	
122-37	19576-19580	this	_	
122-38	19581-19591	particular	_	
122-39	19592-19602	functional	_	
122-40	19603-19615	connectivity	_	
122-41	19616-19621	might	_	
122-42	19622-19624	be	_	
122-43	19625-19632	related	_	
122-44	19633-19635	to	_	
122-45	19636-19639	the	_	
122-46	19640-19651	development	_	
122-47	19652-19654	of	_	
122-48	19655-19663	negative	_	
122-49	19664-19672	symptoms	_	
122-50	19673-19675	of	_	
122-51	19676-19689	schizophrenia	_	
122-52	19689-19690	.	_	

#Text=In addition, the correlation analysis found a significant positive relationship between the right insula-Heschl gyrus connectivity and the PANSS general psychopathology subscale scores, suggesting that an abnormally increased connectivity might contribute to the manifestation of clinical symptoms such as depression and anxiety observed in patients with schizophrenia.
123-1	19691-19693	In	_	
123-2	19694-19702	addition	_	
123-3	19702-19703	,	_	
123-4	19704-19707	the	_	
123-5	19708-19719	correlation	_	
123-6	19720-19728	analysis	_	
123-7	19729-19734	found	_	
123-8	19735-19736	a	_	
123-9	19737-19748	significant	_	
123-10	19749-19757	positive	_	
123-11	19758-19770	relationship	_	
123-12	19771-19778	between	_	
123-13	19779-19782	the	_	
123-14	19783-19788	right	_	
123-15	19789-19802	insula-Heschl	_	
123-16	19803-19808	gyrus	_	
123-17	19809-19821	connectivity	_	
123-18	19822-19825	and	_	
123-19	19826-19829	the	_	
123-20	19830-19835	PANSS	_	
123-21	19836-19843	general	_	
123-22	19844-19859	psychopathology	_	
123-23	19860-19868	subscale	_	
123-24	19869-19875	scores	_	
123-25	19875-19876	,	_	
123-26	19877-19887	suggesting	_	
123-27	19888-19892	that	_	
123-28	19893-19895	an	_	
123-29	19896-19906	abnormally	_	
123-30	19907-19916	increased	_	
123-31	19917-19929	connectivity	_	
123-32	19930-19935	might	_	
123-33	19936-19946	contribute	_	
123-34	19947-19949	to	_	
123-35	19950-19953	the	_	
123-36	19954-19967	manifestation	_	
123-37	19968-19970	of	_	
123-38	19971-19979	clinical	_	
123-39	19980-19988	symptoms	_	
123-40	19989-19993	such	_	
123-41	19994-19996	as	_	
123-42	19997-20007	depression	_	
123-43	20008-20011	and	_	
123-44	20012-20019	anxiety	_	
123-45	20020-20028	observed	_	
123-46	20029-20031	in	_	
123-47	20032-20040	patients	_	
123-48	20041-20045	with	_	
123-49	20046-20059	schizophrenia	_	
123-50	20059-20060	.	_	

#Text=Symptoms of schizophrenia have been attributed to a failure of functional integration or aberrant connectivity among regions or systems of the brain.
124-1	20061-20069	Symptoms	_	
124-2	20070-20072	of	_	
124-3	20073-20086	schizophrenia	_	
124-4	20087-20091	have	_	
124-5	20092-20096	been	_	
124-6	20097-20107	attributed	_	
124-7	20108-20110	to	_	
124-8	20111-20112	a	_	
124-9	20113-20120	failure	_	
124-10	20121-20123	of	_	
124-11	20124-20134	functional	_	
124-12	20135-20146	integration	_	
124-13	20147-20149	or	_	
124-14	20150-20158	aberrant	_	
124-15	20159-20171	connectivity	_	
124-16	20172-20177	among	_	
124-17	20178-20185	regions	_	
124-18	20186-20188	or	_	
124-19	20189-20196	systems	_	
124-20	20197-20199	of	_	
124-21	20200-20203	the	_	
124-22	20204-20209	brain	_	
124-23	20209-20210	.	_	

#Text=Manoliu et al. found that the right anterior insular cortical dysfunction was associated with positive symptoms of schizophrenia during the acute phase of psychosis; they further suggested that the specific SN/DMN/CEN reorganization with distinct insular cortical pathways might be related to different symptom domains of schizophrenia.
125-1	20211-20218	Manoliu	_	
125-2	20219-20221	et	_	
125-3	20222-20224	al	_	
125-4	20224-20225	.	_	
125-5	20226-20231	found	_	
125-6	20232-20236	that	_	
125-7	20237-20240	the	_	
125-8	20241-20246	right	_	
125-9	20247-20255	anterior	_	
125-10	20256-20263	insular	_	
125-11	20264-20272	cortical	_	
125-12	20273-20284	dysfunction	_	
125-13	20285-20288	was	_	
125-14	20289-20299	associated	_	
125-15	20300-20304	with	_	
125-16	20305-20313	positive	_	
125-17	20314-20322	symptoms	_	
125-18	20323-20325	of	_	
125-19	20326-20339	schizophrenia	_	
125-20	20340-20346	during	_	
125-21	20347-20350	the	_	
125-22	20351-20356	acute	_	
125-23	20357-20362	phase	_	
125-24	20363-20365	of	_	
125-25	20366-20375	psychosis	_	
125-26	20375-20376	;	_	
125-27	20377-20381	they	_	
125-28	20382-20389	further	_	
125-29	20390-20399	suggested	_	
125-30	20400-20404	that	_	
125-31	20405-20408	the	_	
125-32	20409-20417	specific	_	
125-33	20418-20420	SN	_	
125-34	20420-20421	/	_	
125-35	20421-20424	DMN	_	
125-36	20424-20425	/	_	
125-37	20425-20428	CEN	_	
125-38	20429-20443	reorganization	_	
125-39	20444-20448	with	_	
125-40	20449-20457	distinct	_	
125-41	20458-20465	insular	_	
125-42	20466-20474	cortical	_	
125-43	20475-20483	pathways	_	
125-44	20484-20489	might	_	
125-45	20490-20492	be	_	
125-46	20493-20500	related	_	
125-47	20501-20503	to	_	
125-48	20504-20513	different	_	
125-49	20514-20521	symptom	_	
125-50	20522-20529	domains	_	
125-51	20530-20532	of	_	
125-52	20533-20546	schizophrenia	_	
125-53	20546-20547	.	_	

#Text=Another study reported that structural alterations of the insular cortex might be related to negative symptoms during psychotic remission, which is consist with our report about the negative correlation between the insular cortex-Heschl’s gyrus connectivity in the left brain hemisphere and the PANSS negative symptoms.
126-1	20548-20555	Another	_	
126-2	20556-20561	study	_	
126-3	20562-20570	reported	_	
126-4	20571-20575	that	_	
126-5	20576-20586	structural	_	
126-6	20587-20598	alterations	_	
126-7	20599-20601	of	_	
126-8	20602-20605	the	_	
126-9	20606-20613	insular	_	
126-10	20614-20620	cortex	_	
126-11	20621-20626	might	_	
126-12	20627-20629	be	_	
126-13	20630-20637	related	_	
126-14	20638-20640	to	_	
126-15	20641-20649	negative	_	
126-16	20650-20658	symptoms	_	
126-17	20659-20665	during	_	
126-18	20666-20675	psychotic	_	
126-19	20676-20685	remission	_	
126-20	20685-20686	,	_	
126-21	20687-20692	which	_	
126-22	20693-20695	is	_	
126-23	20696-20703	consist	_	
126-24	20704-20708	with	_	
126-25	20709-20712	our	_	
126-26	20713-20719	report	_	
126-27	20720-20725	about	_	
126-28	20726-20729	the	_	
126-29	20730-20738	negative	_	
126-30	20739-20750	correlation	_	
126-31	20751-20758	between	_	
126-32	20759-20762	the	_	
126-33	20763-20770	insular	_	
126-34	20771-20784	cortex-Heschl	_	
126-35	20784-20785	’	_	
126-36	20785-20786	s	_	
126-37	20787-20792	gyrus	_	
126-38	20793-20805	connectivity	_	
126-39	20806-20808	in	_	
126-40	20809-20812	the	_	
126-41	20813-20817	left	_	
126-42	20818-20823	brain	_	
126-43	20824-20834	hemisphere	_	
126-44	20835-20838	and	_	
126-45	20839-20842	the	_	
126-46	20843-20848	PANSS	_	
126-47	20849-20857	negative	_	
126-48	20858-20866	symptoms	_	
126-49	20866-20867	.	_	

#Text=Lee et al. reported that progressive gray matter volume reduction in both insular cortex and temporal pole in first episode psychosis was inversely associated with changes in the overall Brief Psychiatric Rating Scale symptom scores.
127-1	20868-20871	Lee	_	
127-2	20872-20874	et	_	
127-3	20875-20877	al	_	
127-4	20877-20878	.	_	
127-5	20879-20887	reported	_	
127-6	20888-20892	that	_	
127-7	20893-20904	progressive	_	
127-8	20905-20909	gray	_	
127-9	20910-20916	matter	_	
127-10	20917-20923	volume	_	
127-11	20924-20933	reduction	_	
127-12	20934-20936	in	_	
127-13	20937-20941	both	_	
127-14	20942-20949	insular	_	
127-15	20950-20956	cortex	_	
127-16	20957-20960	and	_	
127-17	20961-20969	temporal	_	
127-18	20970-20974	pole	_	
127-19	20975-20977	in	_	
127-20	20978-20983	first	_	
127-21	20984-20991	episode	_	
127-22	20992-21001	psychosis	_	
127-23	21002-21005	was	_	
127-24	21006-21015	inversely	_	
127-25	21016-21026	associated	_	
127-26	21027-21031	with	_	
127-27	21032-21039	changes	_	
127-28	21040-21042	in	_	
127-29	21043-21046	the	_	
127-30	21047-21054	overall	_	
127-31	21055-21060	Brief	_	
127-32	21061-21072	Psychiatric	_	
127-33	21073-21079	Rating	_	
127-34	21080-21085	Scale	_	
127-35	21086-21093	symptom	_	
127-36	21094-21100	scores	_	
127-37	21100-21101	.	_	

#Text=Some studies suggested that disturbances in emotional prosody is due to the impairment in early auditory sensory processing, which may contribute to later impairment in attention-dependent processes in schizophrenia.
128-1	21102-21106	Some	_	
128-2	21107-21114	studies	_	
128-3	21115-21124	suggested	_	
128-4	21125-21129	that	_	
128-5	21130-21142	disturbances	_	
128-6	21143-21145	in	_	
128-7	21146-21155	emotional	_	
128-8	21156-21163	prosody	_	
128-9	21164-21166	is	_	
128-10	21167-21170	due	_	
128-11	21171-21173	to	_	
128-12	21174-21177	the	_	
128-13	21178-21188	impairment	_	
128-14	21189-21191	in	_	
128-15	21192-21197	early	_	
128-16	21198-21206	auditory	_	
128-17	21207-21214	sensory	_	
128-18	21215-21225	processing	_	
128-19	21225-21226	,	_	
128-20	21227-21232	which	_	
128-21	21233-21236	may	_	
128-22	21237-21247	contribute	_	
128-23	21248-21250	to	_	
128-24	21251-21256	later	_	
128-25	21257-21267	impairment	_	
128-26	21268-21270	in	_	
128-27	21271-21290	attention-dependent	_	
128-28	21291-21300	processes	_	
128-29	21301-21303	in	_	
128-30	21304-21317	schizophrenia	_	
128-31	21317-21318	.	_	

#Text=It is also reported that the cortical surface area and local white matter volume of posterior insula might play an important role in insight impairment in schizophrenia.
129-1	21319-21321	It	_	
129-2	21322-21324	is	_	
129-3	21325-21329	also	_	
129-4	21330-21338	reported	_	
129-5	21339-21343	that	_	
129-6	21344-21347	the	_	
129-7	21348-21356	cortical	_	
129-8	21357-21364	surface	_	
129-9	21365-21369	area	_	
129-10	21370-21373	and	_	
129-11	21374-21379	local	_	
129-12	21380-21385	white	_	
129-13	21386-21392	matter	_	
129-14	21393-21399	volume	_	
129-15	21400-21402	of	_	
129-16	21403-21412	posterior	_	
129-17	21413-21419	insula	_	
129-18	21420-21425	might	_	
129-19	21426-21430	play	_	
129-20	21431-21433	an	_	
129-21	21434-21443	important	_	
129-22	21444-21448	role	_	
129-23	21449-21451	in	_	
129-24	21452-21459	insight	_	
129-25	21460-21470	impairment	_	
129-26	21471-21473	in	_	
129-27	21474-21487	schizophrenia	_	
129-28	21487-21488	.	_	

#Text=Both attention deficit and insight impairment might be related to the general psychopathology symptoms (depression, anxiety etc.) observed in patients with schizophrenia.
130-1	21489-21493	Both	_	
130-2	21494-21503	attention	_	
130-3	21504-21511	deficit	_	
130-4	21512-21515	and	_	
130-5	21516-21523	insight	_	
130-6	21524-21534	impairment	_	
130-7	21535-21540	might	_	
130-8	21541-21543	be	_	
130-9	21544-21551	related	_	
130-10	21552-21554	to	_	
130-11	21555-21558	the	_	
130-12	21559-21566	general	_	
130-13	21567-21582	psychopathology	_	
130-14	21583-21591	symptoms	_	
130-15	21592-21593	(	_	
130-16	21593-21603	depression	_	
130-17	21603-21604	,	_	
130-18	21605-21612	anxiety	_	
130-19	21613-21616	etc	_	
130-20	21616-21617	.	_	
130-21	21617-21618	)	_	
130-22	21619-21627	observed	_	
130-23	21628-21630	in	_	
130-24	21631-21639	patients	_	
130-25	21640-21644	with	_	
130-26	21645-21658	schizophrenia	_	
130-27	21658-21659	.	_	

#Text=The present study has several limitations: 1) Some meaningful information may have been lost by removing global signal in preprocessing of the imaging data. 2) The patient subjects were recruited from an inpatient unit; the overall symptom severity of the study sample might be higher than patients in the outpatient setting.
131-1	21660-21663	The	_	
131-2	21664-21671	present	_	
131-3	21672-21677	study	_	
131-4	21678-21681	has	_	
131-5	21682-21689	several	_	
131-6	21690-21701	limitations	_	
131-7	21701-21702	:	_	
131-8	21703-21704	1	_	
131-9	21704-21705	)	_	
131-10	21706-21710	Some	_	
131-11	21711-21721	meaningful	_	
131-12	21722-21733	information	_	
131-13	21734-21737	may	_	
131-14	21738-21742	have	_	
131-15	21743-21747	been	_	
131-16	21748-21752	lost	_	
131-17	21753-21755	by	_	
131-18	21756-21764	removing	_	
131-19	21765-21771	global	_	
131-20	21772-21778	signal	_	
131-21	21779-21781	in	_	
131-22	21782-21795	preprocessing	_	
131-23	21796-21798	of	_	
131-24	21799-21802	the	_	
131-25	21803-21810	imaging	_	
131-26	21811-21815	data	_	
131-27	21815-21816	.	_	
131-28	21817-21818	2	_	
131-29	21818-21819	)	_	
131-30	21820-21823	The	_	
131-31	21824-21831	patient	_	
131-32	21832-21840	subjects	_	
131-33	21841-21845	were	_	
131-34	21846-21855	recruited	_	
131-35	21856-21860	from	_	
131-36	21861-21863	an	_	
131-37	21864-21873	inpatient	_	
131-38	21874-21878	unit	_	
131-39	21878-21879	;	_	
131-40	21880-21883	the	_	
131-41	21884-21891	overall	_	
131-42	21892-21899	symptom	_	
131-43	21900-21908	severity	_	
131-44	21909-21911	of	_	
131-45	21912-21915	the	_	
131-46	21916-21921	study	_	
131-47	21922-21928	sample	_	
131-48	21929-21934	might	_	
131-49	21935-21937	be	_	
131-50	21938-21944	higher	_	
131-51	21945-21949	than	_	
131-52	21950-21958	patients	_	
131-53	21959-21961	in	_	
131-54	21962-21965	the	_	
131-55	21966-21976	outpatient	_	
131-56	21977-21984	setting	_	
131-57	21984-21985	.	_	

#Text=Therefore the findings from this study, especially the correlation between functional connectivity and clinical symptoms, may not be generalizable to all patients. 3) The correlation analysis between functional connectivity and clinical symptoms was not corrected for multiple correlations; 4) Several software tools were used for pre-processing and processing of imaging data; 5) The PANSS was the only rating scale used to assess clinical symptoms.
132-1	21986-21995	Therefore	_	
132-2	21996-21999	the	_	
132-3	22000-22008	findings	_	
132-4	22009-22013	from	_	
132-5	22014-22018	this	_	
132-6	22019-22024	study	_	
132-7	22024-22025	,	_	
132-8	22026-22036	especially	_	
132-9	22037-22040	the	_	
132-10	22041-22052	correlation	_	
132-11	22053-22060	between	_	
132-12	22061-22071	functional	_	
132-13	22072-22084	connectivity	_	
132-14	22085-22088	and	_	
132-15	22089-22097	clinical	_	
132-16	22098-22106	symptoms	_	
132-17	22106-22107	,	_	
132-18	22108-22111	may	_	
132-19	22112-22115	not	_	
132-20	22116-22118	be	_	
132-21	22119-22132	generalizable	_	
132-22	22133-22135	to	_	
132-23	22136-22139	all	_	
132-24	22140-22148	patients	_	
132-25	22148-22149	.	_	
132-26	22150-22151	3	_	
132-27	22151-22152	)	_	
132-28	22153-22156	The	_	
132-29	22157-22168	correlation	_	
132-30	22169-22177	analysis	_	
132-31	22178-22185	between	_	
132-32	22186-22196	functional	_	
132-33	22197-22209	connectivity	_	
132-34	22210-22213	and	_	
132-35	22214-22222	clinical	_	
132-36	22223-22231	symptoms	_	
132-37	22232-22235	was	_	
132-38	22236-22239	not	_	
132-39	22240-22249	corrected	_	
132-40	22250-22253	for	_	
132-41	22254-22262	multiple	_	
132-42	22263-22275	correlations	_	
132-43	22275-22276	;	_	
132-44	22277-22278	4	_	
132-45	22278-22279	)	_	
132-46	22280-22287	Several	_	
132-47	22288-22296	software	_	
132-48	22297-22302	tools	_	
132-49	22303-22307	were	_	
132-50	22308-22312	used	_	
132-51	22313-22316	for	_	
132-52	22317-22331	pre-processing	_	
132-53	22332-22335	and	_	
132-54	22336-22346	processing	_	
132-55	22347-22349	of	_	
132-56	22350-22357	imaging	_	
132-57	22358-22362	data	_	
132-58	22362-22363	;	_	
132-59	22364-22365	5	_	
132-60	22365-22366	)	_	
132-61	22367-22370	The	_	
132-62	22371-22376	PANSS	_	
132-63	22377-22380	was	_	
132-64	22381-22384	the	_	
132-65	22385-22389	only	_	
132-66	22390-22396	rating	_	
132-67	22397-22402	scale	_	
132-68	22403-22407	used	_	
132-69	22408-22410	to	_	
132-70	22411-22417	assess	_	
132-71	22418-22426	clinical	_	
132-72	22427-22435	symptoms	_	
132-73	22435-22436	.	_	

#Text=In summary, our study demonstrates the abnormal functional connectivity of insula, insula-Heschl gyrus connectivity in particular, in drug naïve, first episode schizophrenia patients.
133-1	22437-22439	In	_	
133-2	22440-22447	summary	_	
133-3	22447-22448	,	_	
133-4	22449-22452	our	_	
133-5	22453-22458	study	_	
133-6	22459-22471	demonstrates	_	
133-7	22472-22475	the	_	
133-8	22476-22484	abnormal	_	
133-9	22485-22495	functional	_	
133-10	22496-22508	connectivity	_	
133-11	22509-22511	of	_	
133-12	22512-22518	insula	_	
133-13	22518-22519	,	_	
133-14	22520-22533	insula-Heschl	_	
133-15	22534-22539	gyrus	_	
133-16	22540-22552	connectivity	_	
133-17	22553-22555	in	_	
133-18	22556-22566	particular	_	
133-19	22566-22567	,	_	
133-20	22568-22570	in	_	
133-21	22571-22575	drug	_	
133-22	22576-22581	naïve	_	
133-23	22581-22582	,	_	
133-24	22583-22588	first	_	
133-25	22589-22596	episode	_	
133-26	22597-22610	schizophrenia	_	
133-27	22611-22619	patients	_	
133-28	22619-22620	.	_	

#Text=These abnormalities might contribute to the development of schizophrenia.
134-1	22621-22626	These	_	
134-2	22627-22640	abnormalities	_	
134-3	22641-22646	might	_	
134-4	22647-22657	contribute	_	
134-5	22658-22660	to	_	
134-6	22661-22664	the	_	
134-7	22665-22676	development	_	
134-8	22677-22679	of	_	
134-9	22680-22693	schizophrenia	_	
134-10	22693-22694	.	_	

#Text=Future studies with a larger sample size and in combination with other techniques such as diffusion tensor imaging (DTI) are needed to further assess the regions of insular connectivity in relation to the development and treatment of schizophrenia.
135-1	22695-22701	Future	_	
135-2	22702-22709	studies	_	
135-3	22710-22714	with	_	
135-4	22715-22716	a	_	
135-5	22717-22723	larger	_	
135-6	22724-22730	sample	_	
135-7	22731-22735	size	_	
135-8	22736-22739	and	_	
135-9	22740-22742	in	_	
135-10	22743-22754	combination	_	
135-11	22755-22759	with	_	
135-12	22760-22765	other	_	
135-13	22766-22776	techniques	_	
135-14	22777-22781	such	_	
135-15	22782-22784	as	_	
135-16	22785-22794	diffusion	_	
135-17	22795-22801	tensor	_	
135-18	22802-22809	imaging	_	
135-19	22810-22811	(	_	
135-20	22811-22814	DTI	_	
135-21	22814-22815	)	_	
135-22	22816-22819	are	_	
135-23	22820-22826	needed	_	
135-24	22827-22829	to	_	
135-25	22830-22837	further	_	
135-26	22838-22844	assess	_	
135-27	22845-22848	the	_	
135-28	22849-22856	regions	_	
135-29	22857-22859	of	_	
135-30	22860-22867	insular	_	
135-31	22868-22880	connectivity	_	
135-32	22881-22883	in	_	
135-33	22884-22892	relation	_	
135-34	22893-22895	to	_	
135-35	22896-22899	the	_	
135-36	22900-22911	development	_	
135-37	22912-22915	and	_	
135-38	22916-22925	treatment	_	
135-39	22926-22928	of	_	
135-40	22929-22942	schizophrenia	_	
135-41	22942-22943	.	_	

#Text=Supporting Information
#Text=References
#Text=A cross-national factor analytic comparison of three models of PANSS symptoms in schizophrenia
#Text=Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon?
136-1	22944-22954	Supporting	_	
136-2	22955-22966	Information	_	
136-3	22967-22977	References	_	
136-4	22978-22979	A	_	
136-5	22980-22994	cross-national	_	
136-6	22995-23001	factor	_	
136-7	23002-23010	analytic	_	
136-8	23011-23021	comparison	_	
136-9	23022-23024	of	_	
136-10	23025-23030	three	_	
136-11	23031-23037	models	_	
136-12	23038-23040	of	_	
136-13	23041-23046	PANSS	_	
136-14	23047-23055	symptoms	_	
136-15	23056-23058	in	_	
136-16	23059-23072	schizophrenia	_	
136-17	23073-23082	Disturbed	_	
136-18	23083-23093	structural	_	
136-19	23094-23106	connectivity	_	
136-20	23107-23109	in	_	
136-21	23110-23123	schizophrenia	_	
136-22	23124-23131	primary	_	
136-23	23132-23138	factor	_	
136-24	23139-23141	in	_	
136-25	23142-23151	pathology	_	
136-26	23152-23154	or	_	
136-27	23155-23168	epiphenomenon	_	
136-28	23168-23169	?	_	

#Text=Large-scale brain networks and psychopathology: a unifying triple network model
#Text=Are Auditory Hallucinations Related to the Brain's Resting State Activity?
137-1	23170-23181	Large-scale	_	
137-2	23182-23187	brain	_	
137-3	23188-23196	networks	_	
137-4	23197-23200	and	_	
137-5	23201-23216	psychopathology	_	
137-6	23216-23217	:	_	
137-7	23218-23219	a	_	
137-8	23220-23228	unifying	_	
137-9	23229-23235	triple	_	
137-10	23236-23243	network	_	
137-11	23244-23249	model	_	
137-12	23250-23253	Are	_	
137-13	23254-23262	Auditory	_	
137-14	23263-23277	Hallucinations	_	
137-15	23278-23285	Related	_	
137-16	23286-23288	to	_	
137-17	23289-23292	the	_	
137-18	23293-23300	Brain's	_	
137-19	23301-23308	Resting	_	
137-20	23309-23314	State	_	
137-21	23315-23323	Activity	_	
137-22	23323-23324	?	_	

#Text=A 'Neurophenomenal Resting State Hypothesis'
#Text=The relation between neurocognitive dysfunction and impaired insight in patients with schizophrenia
#Text=Functional connectivity of the insula in the resting brain
#Text=Does the salience network play a cardinal role in psychosis?
138-1	23325-23326	A	_	
138-2	23327-23328	'	_	
138-3	23328-23343	Neurophenomenal	_	
138-4	23344-23351	Resting	_	
138-5	23352-23357	State	_	
138-6	23358-23368	Hypothesis	_	
138-7	23368-23369	'	_	
138-8	23370-23373	The	_	
138-9	23374-23382	relation	_	
138-10	23383-23390	between	_	
138-11	23391-23405	neurocognitive	_	
138-12	23406-23417	dysfunction	_	
138-13	23418-23421	and	_	
138-14	23422-23430	impaired	_	
138-15	23431-23438	insight	_	
138-16	23439-23441	in	_	
138-17	23442-23450	patients	_	
138-18	23451-23455	with	_	
138-19	23456-23469	schizophrenia	_	
138-20	23470-23480	Functional	_	
138-21	23481-23493	connectivity	_	
138-22	23494-23496	of	_	
138-23	23497-23500	the	_	
138-24	23501-23507	insula	_	
138-25	23508-23510	in	_	
138-26	23511-23514	the	_	
138-27	23515-23522	resting	_	
138-28	23523-23528	brain	_	
138-29	23529-23533	Does	_	
138-30	23534-23537	the	_	
138-31	23538-23546	salience	_	
138-32	23547-23554	network	_	
138-33	23555-23559	play	_	
138-34	23560-23561	a	_	
138-35	23562-23570	cardinal	_	
138-36	23571-23575	role	_	
138-37	23576-23578	in	_	
138-38	23579-23588	psychosis	_	
138-39	23588-23589	?	_	

#Text=An emerging hypothesis of insular dysfunction
#Text=Abnormal insula functional network is associated with episodic memory decline in amnestic mild cognitive impairment
#Text=Impaired executive functioning after left anterior insular stroke: a case report
#Text=Role of the anterior insula in task-level control and focal attention
#Text=Saliency, switching, attention and control: a network model of insula function
#Text=The role of the insula in schizophrenia
#Text=Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression
#Text=Gray and white matter volumetric and diffusion tensor imaging (DTI) analyses in the early stage of first-episode schizophrenia
#Text=Lack of insula reactivity to aversive stimuli in schizophrenia
#Text=Insular Dysfunction Reflects Altered Between-Network Connectivity and Severity of Negative Symptoms in Schizophrenia during Psychotic Remission
#Text=Aberrant dependence of default mode/central executive network interactions on anterior insular salience network activity in schizophrenia
#Text=Disruption of anterior insula modulation of large-scale brain networks in schizophrenia
#Text=The insula-claustrum region and delusions in schizophrenia
#Text=Reality distortion is related to the structure of the salience network in schizophrenia
#Text=Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia
#Text=Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment
#Text=The positive and negative syndrome scale (PANSS) for schizophrenia
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=Largely typical patterns of resting-state functional connectivity in high-functioning adults with autism
#Text=Human cerebral cortex: localization, parcellation, and morphometry with magnetic resonance imaging
#Text=Voxel-based morphometry—the methods
#Text=Planum temporale and Heschl gyrus volume reduction in schizophrenia: a magnetic resonance imaging study of first-episode patients
#Text=Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study
#Text=Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis
#Text=The neural substrates of impaired prosodic detection in schizophrenia and its sensorial antecedents
#Text=The cognitive functions of the caudate nucleus
#Text=Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia
#Text=Caudate volume in offspring of patients with schizophrenia
#Text=White matter integrity and lack of insight in schizophrenia and schizoaffective disorder
#Text=Is avolition in schizophrenia associated with a deficit of dorsal caudate activity?
139-1	23590-23592	An	_	
139-2	23593-23601	emerging	_	
139-3	23602-23612	hypothesis	_	
139-4	23613-23615	of	_	
139-5	23616-23623	insular	_	
139-6	23624-23635	dysfunction	_	
139-7	23636-23644	Abnormal	_	
139-8	23645-23651	insula	_	
139-9	23652-23662	functional	_	
139-10	23663-23670	network	_	
139-11	23671-23673	is	_	
139-12	23674-23684	associated	_	
139-13	23685-23689	with	_	
139-14	23690-23698	episodic	_	
139-15	23699-23705	memory	_	
139-16	23706-23713	decline	_	
139-17	23714-23716	in	_	
139-18	23717-23725	amnestic	_	
139-19	23726-23730	mild	_	
139-20	23731-23740	cognitive	_	
139-21	23741-23751	impairment	_	
139-22	23752-23760	Impaired	_	
139-23	23761-23770	executive	_	
139-24	23771-23782	functioning	_	
139-25	23783-23788	after	_	
139-26	23789-23793	left	_	
139-27	23794-23802	anterior	_	
139-28	23803-23810	insular	_	
139-29	23811-23817	stroke	_	
139-30	23817-23818	:	_	
139-31	23819-23820	a	_	
139-32	23821-23825	case	_	
139-33	23826-23832	report	_	
139-34	23833-23837	Role	_	
139-35	23838-23840	of	_	
139-36	23841-23844	the	_	
139-37	23845-23853	anterior	_	
139-38	23854-23860	insula	_	
139-39	23861-23863	in	_	
139-40	23864-23874	task-level	_	
139-41	23875-23882	control	_	
139-42	23883-23886	and	_	
139-43	23887-23892	focal	_	
139-44	23893-23902	attention	_	
139-45	23903-23911	Saliency	_	
139-46	23911-23912	,	_	
139-47	23913-23922	switching	_	
139-48	23922-23923	,	_	
139-49	23924-23933	attention	_	
139-50	23934-23937	and	_	
139-51	23938-23945	control	_	
139-52	23945-23946	:	_	
139-53	23947-23948	a	_	
139-54	23949-23956	network	_	
139-55	23957-23962	model	_	
139-56	23963-23965	of	_	
139-57	23966-23972	insula	_	
139-58	23973-23981	function	_	
139-59	23982-23985	The	_	
139-60	23986-23990	role	_	
139-61	23991-23993	of	_	
139-62	23994-23997	the	_	
139-63	23998-24004	insula	_	
139-64	24005-24007	in	_	
139-65	24008-24021	schizophrenia	_	
139-66	24022-24027	Brain	_	
139-67	24028-24038	anatomical	_	
139-68	24039-24052	abnormalities	_	
139-69	24053-24055	in	_	
139-70	24056-24065	high-risk	_	
139-71	24066-24077	individuals	_	
139-72	24077-24078	,	_	
139-73	24079-24092	first-episode	_	
139-74	24092-24093	,	_	
139-75	24094-24097	and	_	
139-76	24098-24105	chronic	_	
139-77	24106-24119	schizophrenia	_	
139-78	24119-24120	:	_	
139-79	24121-24123	an	_	
139-80	24124-24134	activation	_	
139-81	24135-24145	likelihood	_	
139-82	24146-24156	estimation	_	
139-83	24157-24170	meta-analysis	_	
139-84	24171-24173	of	_	
139-85	24174-24181	illness	_	
139-86	24182-24193	progression	_	
139-87	24194-24198	Gray	_	
139-88	24199-24202	and	_	
139-89	24203-24208	white	_	
139-90	24209-24215	matter	_	
139-91	24216-24226	volumetric	_	
139-92	24227-24230	and	_	
139-93	24231-24240	diffusion	_	
139-94	24241-24247	tensor	_	
139-95	24248-24255	imaging	_	
139-96	24256-24257	(	_	
139-97	24257-24260	DTI	_	
139-98	24260-24261	)	_	
139-99	24262-24270	analyses	_	
139-100	24271-24273	in	_	
139-101	24274-24277	the	_	
139-102	24278-24283	early	_	
139-103	24284-24289	stage	_	
139-104	24290-24292	of	_	
139-105	24293-24306	first-episode	_	
139-106	24307-24320	schizophrenia	_	
139-107	24321-24325	Lack	_	
139-108	24326-24328	of	_	
139-109	24329-24335	insula	_	
139-110	24336-24346	reactivity	_	
139-111	24347-24349	to	_	
139-112	24350-24358	aversive	_	
139-113	24359-24366	stimuli	_	
139-114	24367-24369	in	_	
139-115	24370-24383	schizophrenia	_	
139-116	24384-24391	Insular	_	
139-117	24392-24403	Dysfunction	_	
139-118	24404-24412	Reflects	_	
139-119	24413-24420	Altered	_	
139-120	24421-24436	Between-Network	_	
139-121	24437-24449	Connectivity	_	
139-122	24450-24453	and	_	
139-123	24454-24462	Severity	_	
139-124	24463-24465	of	_	
139-125	24466-24474	Negative	_	
139-126	24475-24483	Symptoms	_	
139-127	24484-24486	in	_	
139-128	24487-24500	Schizophrenia	_	
139-129	24501-24507	during	_	
139-130	24508-24517	Psychotic	_	
139-131	24518-24527	Remission	_	
139-132	24528-24536	Aberrant	_	
139-133	24537-24547	dependence	_	
139-134	24548-24550	of	_	
139-135	24551-24558	default	_	
139-136	24559-24563	mode	_	
139-137	24563-24564	/	_	
139-138	24564-24571	central	_	
139-139	24572-24581	executive	_	
139-140	24582-24589	network	_	
139-141	24590-24602	interactions	_	
139-142	24603-24605	on	_	
139-143	24606-24614	anterior	_	
139-144	24615-24622	insular	_	
139-145	24623-24631	salience	_	
139-146	24632-24639	network	_	
139-147	24640-24648	activity	_	
139-148	24649-24651	in	_	
139-149	24652-24665	schizophrenia	_	
139-150	24666-24676	Disruption	_	
139-151	24677-24679	of	_	
139-152	24680-24688	anterior	_	
139-153	24689-24695	insula	_	
139-154	24696-24706	modulation	_	
139-155	24707-24709	of	_	
139-156	24710-24721	large-scale	_	
139-157	24722-24727	brain	_	
139-158	24728-24736	networks	_	
139-159	24737-24739	in	_	
139-160	24740-24753	schizophrenia	_	
139-161	24754-24757	The	_	
139-162	24758-24774	insula-claustrum	_	
139-163	24775-24781	region	_	
139-164	24782-24785	and	_	
139-165	24786-24795	delusions	_	
139-166	24796-24798	in	_	
139-167	24799-24812	schizophrenia	_	
139-168	24813-24820	Reality	_	
139-169	24821-24831	distortion	_	
139-170	24832-24834	is	_	
139-171	24835-24842	related	_	
139-172	24843-24845	to	_	
139-173	24846-24849	the	_	
139-174	24850-24859	structure	_	
139-175	24860-24862	of	_	
139-176	24863-24866	the	_	
139-177	24867-24875	salience	_	
139-178	24876-24883	network	_	
139-179	24884-24886	in	_	
139-180	24887-24900	schizophrenia	_	
139-181	24901-24908	Ventral	_	
139-182	24909-24918	tegmental	_	
139-183	24919-24923	area	_	
139-184	24923-24924	/	_	
139-185	24924-24932	midbrain	_	
139-186	24933-24943	functional	_	
139-187	24944-24956	connectivity	_	
139-188	24957-24960	and	_	
139-189	24961-24969	response	_	
139-190	24970-24972	to	_	
139-191	24973-24986	antipsychotic	_	
139-192	24987-24997	medication	_	
139-193	24998-25000	in	_	
139-194	25001-25014	schizophrenia	_	
139-195	25015-25023	Baseline	_	
139-196	25024-25032	Striatal	_	
139-197	25033-25043	Functional	_	
139-198	25044-25056	Connectivity	_	
139-199	25057-25059	as	_	
139-200	25060-25061	a	_	
139-201	25062-25071	Predictor	_	
139-202	25072-25074	of	_	
139-203	25075-25083	Response	_	
139-204	25084-25086	to	_	
139-205	25087-25100	Antipsychotic	_	
139-206	25101-25105	Drug	_	
139-207	25106-25115	Treatment	_	
139-208	25116-25119	The	_	
139-209	25120-25128	positive	_	
139-210	25129-25132	and	_	
139-211	25133-25141	negative	_	
139-212	25142-25150	syndrome	_	
139-213	25151-25156	scale	_	
139-214	25157-25158	(	_	
139-215	25158-25163	PANSS	_	
139-216	25163-25164	)	_	
139-217	25165-25168	for	_	
139-218	25169-25182	schizophrenia	_	
139-219	25183-25187	AFNI	_	
139-220	25187-25188	:	_	
139-221	25189-25197	software	_	
139-222	25198-25201	for	_	
139-223	25202-25210	analysis	_	
139-224	25211-25214	and	_	
139-225	25215-25228	visualization	_	
139-226	25229-25231	of	_	
139-227	25232-25242	functional	_	
139-228	25243-25251	magnetic	_	
139-229	25252-25261	resonance	_	
139-230	25262-25273	neuroimages	_	
139-231	25274-25281	Largely	_	
139-232	25282-25289	typical	_	
139-233	25290-25298	patterns	_	
139-234	25299-25301	of	_	
139-235	25302-25315	resting-state	_	
139-236	25316-25326	functional	_	
139-237	25327-25339	connectivity	_	
139-238	25340-25342	in	_	
139-239	25343-25359	high-functioning	_	
139-240	25360-25366	adults	_	
139-241	25367-25371	with	_	
139-242	25372-25378	autism	_	
139-243	25379-25384	Human	_	
139-244	25385-25393	cerebral	_	
139-245	25394-25400	cortex	_	
139-246	25400-25401	:	_	
139-247	25402-25414	localization	_	
139-248	25414-25415	,	_	
139-249	25416-25428	parcellation	_	
139-250	25428-25429	,	_	
139-251	25430-25433	and	_	
139-252	25434-25445	morphometry	_	
139-253	25446-25450	with	_	
139-254	25451-25459	magnetic	_	
139-255	25460-25469	resonance	_	
139-256	25470-25477	imaging	_	
139-257	25478-25489	Voxel-based	_	
139-258	25490-25505	morphometry—the	_	
139-259	25506-25513	methods	_	
139-260	25514-25520	Planum	_	
139-261	25521-25530	temporale	_	
139-262	25531-25534	and	_	
139-263	25535-25541	Heschl	_	
139-264	25542-25547	gyrus	_	
139-265	25548-25554	volume	_	
139-266	25555-25564	reduction	_	
139-267	25565-25567	in	_	
139-268	25568-25581	schizophrenia	_	
139-269	25581-25582	:	_	
139-270	25583-25584	a	_	
139-271	25585-25593	magnetic	_	
139-272	25594-25603	resonance	_	
139-273	25604-25611	imaging	_	
139-274	25612-25617	study	_	
139-275	25618-25620	of	_	
139-276	25621-25634	first-episode	_	
139-277	25635-25643	patients	_	
139-278	25644-25655	Progressive	_	
139-279	25656-25664	decrease	_	
139-280	25665-25667	of	_	
139-281	25668-25672	left	_	
139-282	25673-25679	Heschl	_	
139-283	25680-25685	gyrus	_	
139-284	25686-25689	and	_	
139-285	25690-25696	planum	_	
139-286	25697-25706	temporale	_	
139-287	25707-25711	gray	_	
139-288	25712-25718	matter	_	
139-289	25719-25725	volume	_	
139-290	25726-25728	in	_	
139-291	25729-25742	first-episode	_	
139-292	25743-25756	schizophrenia	_	
139-293	25756-25757	:	_	
139-294	25758-25759	a	_	
139-295	25760-25772	longitudinal	_	
139-296	25773-25781	magnetic	_	
139-297	25782-25791	resonance	_	
139-298	25792-25799	imaging	_	
139-299	25800-25805	study	_	
139-300	25806-25817	Progressive	_	
139-301	25818-25822	gray	_	
139-302	25823-25829	matter	_	
139-303	25830-25839	reduction	_	
139-304	25840-25842	of	_	
139-305	25843-25846	the	_	
139-306	25847-25855	superior	_	
139-307	25856-25864	temporal	_	
139-308	25865-25870	gyrus	_	
139-309	25871-25877	during	_	
139-310	25878-25888	transition	_	
139-311	25889-25891	to	_	
139-312	25892-25901	psychosis	_	
139-313	25902-25905	The	_	
139-314	25906-25912	neural	_	
139-315	25913-25923	substrates	_	
139-316	25924-25926	of	_	
139-317	25927-25935	impaired	_	
139-318	25936-25944	prosodic	_	
139-319	25945-25954	detection	_	
139-320	25955-25957	in	_	
139-321	25958-25971	schizophrenia	_	
139-322	25972-25975	and	_	
139-323	25976-25979	its	_	
139-324	25980-25989	sensorial	_	
139-325	25990-26001	antecedents	_	
139-326	26002-26005	The	_	
139-327	26006-26015	cognitive	_	
139-328	26016-26025	functions	_	
139-329	26026-26028	of	_	
139-330	26029-26032	the	_	
139-331	26033-26040	caudate	_	
139-332	26041-26048	nucleus	_	
139-333	26049-26056	Caudate	_	
139-334	26057-26064	nucleus	_	
139-335	26065-26071	volume	_	
139-336	26072-26075	and	_	
139-337	26076-26079	its	_	
139-338	26080-26088	clinical	_	
139-339	26089-26092	and	_	
139-340	26093-26102	cognitive	_	
139-341	26103-26115	correlations	_	
139-342	26116-26118	in	_	
139-343	26119-26124	first	_	
139-344	26125-26132	episode	_	
139-345	26133-26146	schizophrenia	_	
139-346	26147-26154	Caudate	_	
139-347	26155-26161	volume	_	
139-348	26162-26164	in	_	
139-349	26165-26174	offspring	_	
139-350	26175-26177	of	_	
139-351	26178-26186	patients	_	
139-352	26187-26191	with	_	
139-353	26192-26205	schizophrenia	_	
139-354	26206-26211	White	_	
139-355	26212-26218	matter	_	
139-356	26219-26228	integrity	_	
139-357	26229-26232	and	_	
139-358	26233-26237	lack	_	
139-359	26238-26240	of	_	
139-360	26241-26248	insight	_	
139-361	26249-26251	in	_	
139-362	26252-26265	schizophrenia	_	
139-363	26266-26269	and	_	
139-364	26270-26285	schizoaffective	_	
139-365	26286-26294	disorder	_	
139-366	26295-26297	Is	_	
139-367	26298-26307	avolition	_	
139-368	26308-26310	in	_	
139-369	26311-26324	schizophrenia	_	
139-370	26325-26335	associated	_	
139-371	26336-26340	with	_	
139-372	26341-26342	a	_	
139-373	26343-26350	deficit	_	
139-374	26351-26353	of	_	
139-375	26354-26360	dorsal	_	
139-376	26361-26368	caudate	_	
139-377	26369-26377	activity	_	
139-378	26377-26378	?	_	

#Text=A functional magnetic resonance imaging study during reward anticipation and feedback
#Text=Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia
#Text=Dissociable intrinsic connectivity networks for salience processing and executive control
#Text=Two systems of resting state connectivity between the insula and cingulate cortex
#Text=Structural connectivity of the salience-executive loop in schizophrenia
#Text=Brain functional connectivity of male patients in remission after the first episode of schizophrenia
#Text=Abnormal neural processing during emotional salience attribution of affective asymmetry in patients with schizophrenia
#Text=Bridging disparate symptoms of schizophrenia: a triple network dysfunction theory
#Text=Links among resting-state default-mode network, salience network, and symptomatology in schizophrenia
#Text=Schizophrenia and the disconnection hypothesis
#Text=Initial and Progressive Gray Matter Abnormalities in Insular Gyrus and Temporal Pole in First-Episode Schizophrenia Contrasted With First-Episode Affective Psychosis
#Text=Impaired recognition and expression of emotional prosody in schizophrenia: review and meta-analysis
#Text=Appreciating symptoms and deficits in schizophrenia: right posterior insula and poor insight
140-1	26379-26380	A	_	
140-2	26381-26391	functional	_	
140-3	26392-26400	magnetic	_	
140-4	26401-26410	resonance	_	
140-5	26411-26418	imaging	_	
140-6	26419-26424	study	_	
140-7	26425-26431	during	_	
140-8	26432-26438	reward	_	
140-9	26439-26451	anticipation	_	
140-10	26452-26455	and	_	
140-11	26456-26464	feedback	_	
140-12	26465-26478	Abnormalities	_	
140-13	26479-26481	in	_	
140-14	26482-26493	hemispheric	_	
140-15	26494-26508	specialization	_	
140-16	26509-26511	of	_	
140-17	26512-26519	caudate	_	
140-18	26520-26527	nucleus	_	
140-19	26528-26540	connectivity	_	
140-20	26541-26543	in	_	
140-21	26544-26557	schizophrenia	_	
140-22	26558-26569	Dissociable	_	
140-23	26570-26579	intrinsic	_	
140-24	26580-26592	connectivity	_	
140-25	26593-26601	networks	_	
140-26	26602-26605	for	_	
140-27	26606-26614	salience	_	
140-28	26615-26625	processing	_	
140-29	26626-26629	and	_	
140-30	26630-26639	executive	_	
140-31	26640-26647	control	_	
140-32	26648-26651	Two	_	
140-33	26652-26659	systems	_	
140-34	26660-26662	of	_	
140-35	26663-26670	resting	_	
140-36	26671-26676	state	_	
140-37	26677-26689	connectivity	_	
140-38	26690-26697	between	_	
140-39	26698-26701	the	_	
140-40	26702-26708	insula	_	
140-41	26709-26712	and	_	
140-42	26713-26722	cingulate	_	
140-43	26723-26729	cortex	_	
140-44	26730-26740	Structural	_	
140-45	26741-26753	connectivity	_	
140-46	26754-26756	of	_	
140-47	26757-26760	the	_	
140-48	26761-26779	salience-executive	_	
140-49	26780-26784	loop	_	
140-50	26785-26787	in	_	
140-51	26788-26801	schizophrenia	_	
140-52	26802-26807	Brain	_	
140-53	26808-26818	functional	_	
140-54	26819-26831	connectivity	_	
140-55	26832-26834	of	_	
140-56	26835-26839	male	_	
140-57	26840-26848	patients	_	
140-58	26849-26851	in	_	
140-59	26852-26861	remission	_	
140-60	26862-26867	after	_	
140-61	26868-26871	the	_	
140-62	26872-26877	first	_	
140-63	26878-26885	episode	_	
140-64	26886-26888	of	_	
140-65	26889-26902	schizophrenia	_	
140-66	26903-26911	Abnormal	_	
140-67	26912-26918	neural	_	
140-68	26919-26929	processing	_	
140-69	26930-26936	during	_	
140-70	26937-26946	emotional	_	
140-71	26947-26955	salience	_	
140-72	26956-26967	attribution	_	
140-73	26968-26970	of	_	
140-74	26971-26980	affective	_	
140-75	26981-26990	asymmetry	_	
140-76	26991-26993	in	_	
140-77	26994-27002	patients	_	
140-78	27003-27007	with	_	
140-79	27008-27021	schizophrenia	_	
140-80	27022-27030	Bridging	_	
140-81	27031-27040	disparate	_	
140-82	27041-27049	symptoms	_	
140-83	27050-27052	of	_	
140-84	27053-27066	schizophrenia	_	
140-85	27066-27067	:	_	
140-86	27068-27069	a	_	
140-87	27070-27076	triple	_	
140-88	27077-27084	network	_	
140-89	27085-27096	dysfunction	_	
140-90	27097-27103	theory	_	
140-91	27104-27109	Links	_	
140-92	27110-27115	among	_	
140-93	27116-27129	resting-state	_	
140-94	27130-27142	default-mode	_	
140-95	27143-27150	network	_	
140-96	27150-27151	,	_	
140-97	27152-27160	salience	_	
140-98	27161-27168	network	_	
140-99	27168-27169	,	_	
140-100	27170-27173	and	_	
140-101	27174-27188	symptomatology	_	
140-102	27189-27191	in	_	
140-103	27192-27205	schizophrenia	_	
140-104	27206-27219	Schizophrenia	_	
140-105	27220-27223	and	_	
140-106	27224-27227	the	_	
140-107	27228-27241	disconnection	_	
140-108	27242-27252	hypothesis	_	
140-109	27253-27260	Initial	_	
140-110	27261-27264	and	_	
140-111	27265-27276	Progressive	_	
140-112	27277-27281	Gray	_	
140-113	27282-27288	Matter	_	
140-114	27289-27302	Abnormalities	_	
140-115	27303-27305	in	_	
140-116	27306-27313	Insular	_	
140-117	27314-27319	Gyrus	_	
140-118	27320-27323	and	_	
140-119	27324-27332	Temporal	_	
140-120	27333-27337	Pole	_	
140-121	27338-27340	in	_	
140-122	27341-27354	First-Episode	_	
140-123	27355-27368	Schizophrenia	_	
140-124	27369-27379	Contrasted	_	
140-125	27380-27384	With	_	
140-126	27385-27398	First-Episode	_	
140-127	27399-27408	Affective	_	
140-128	27409-27418	Psychosis	_	
140-129	27419-27427	Impaired	_	
140-130	27428-27439	recognition	_	
140-131	27440-27443	and	_	
140-132	27444-27454	expression	_	
140-133	27455-27457	of	_	
140-134	27458-27467	emotional	_	
140-135	27468-27475	prosody	_	
140-136	27476-27478	in	_	
140-137	27479-27492	schizophrenia	_	
140-138	27492-27493	:	_	
140-139	27494-27500	review	_	
140-140	27501-27504	and	_	
140-141	27505-27518	meta-analysis	_	
140-142	27519-27531	Appreciating	_	
140-143	27532-27540	symptoms	_	
140-144	27541-27544	and	_	
140-145	27545-27553	deficits	_	
140-146	27554-27556	in	_	
140-147	27557-27570	schizophrenia	_	
140-148	27570-27571	:	_	
140-149	27572-27577	right	_	
140-150	27578-27587	posterior	_	
140-151	27588-27594	insula	_	
140-152	27595-27598	and	_	
140-153	27599-27603	poor	_	
140-154	27604-27611	insight	_	
